var title_f17_0_17408="Radiograph onion skinning Ewing sarcoma";
var content_f17_0_17408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Radiograph onion skinning Ewing sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"Onion skin\" periosteal reaction AP (left panel) and lateral (right panel) view of the distal femur in a 15-year-old girl with Ewing sarcoma. Multiple layers of periosteal reaction simulate the appearance of the layers of an onion's skin. Note the disruption of the outermost layer and the soft tissue mass, suggestive of a malignant process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17408=[""].join("\n");
var outline_f17_0_17408=null;
var title_f17_0_17409="SEER survival gast CA";
var content_f17_0_17409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Observed survival rates for 10,601 surgically resected gastric adenocarcinomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 552px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the SEER 1973-2005 Public Use File diagnosed in years 1991-2000. Stage IA includes 1194; Stage IB, 655; Stage IIA, 1161; Stage IIB, 1195; Stage IIIA; 1031; Stage IIIB, 1660; Stage IIIC, 1053; and stage IV, 6148.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17409=[""].join("\n");
var outline_f17_0_17409=null;
var title_f17_0_17410="Herpes simplex labialis";
var content_f17_0_17410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Herpes simplex labialis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Grouped vesicles are evident on the lower vermilion border.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley LS, Szilagyi P. Bates' Guide to Physical Examination and History Taking, Eighth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17410=[""].join("\n");
var outline_f17_0_17410=null;
var title_f17_0_17411="Parasternal echo aortic valve vegetations";
var content_f17_0_17411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parasteranl long and short axis echocardiogram views showing aortic valve vegetations in patient with endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The precordial views from the transthoracic echocardiogram shows multiple bulky venetations (white arrows) and abscesses (red arrows) of the aortic valve and root. These images were obtained digitally and are displayed in quadrant screen format. In spite of insensitivity for smaller vegetations, precordial transthoracic imaging is often effective for imaging vegetations.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; LA: left atrium; MV: mitral valve.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17411=[""].join("\n");
var outline_f17_0_17411=null;
var title_f17_0_17412="U-S choriocarcinoma";
var content_f17_0_17412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ultrasound choriocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Choriocarcinoma: Patient with stage 3 choriocarcinoma after term pregnancy. The endometrial cavity is filled with a hyperechoic mass measuring 3.0 x 2.9 x 2.8 cm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Department of Radiology, Santa Clara Valley Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17412=[""].join("\n");
var outline_f17_0_17412=null;
var title_f17_0_17413="Bacitracin, neomycin, polymyxin B, and hydrocortisone: Drug information";
var content_f17_0_17413=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bacitracin, neomycin, polymyxin B, and hydrocortisone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/53/30548?source=see_link\">",
"    see \"Bacitracin, neomycin, polymyxin B, and hydrocortisone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/56/43908?source=see_link\">",
"    see \"Bacitracin, neomycin, polymyxin B, and hydrocortisone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cortisporin&reg; Ointment;",
"     </li>",
"     <li>",
"      Neo-Polycin&trade; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cortisporin&reg; Topical Ointment",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F138829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ophthalmic;",
"     </li>",
"     <li>",
"      Antibiotic, Topical;",
"     </li>",
"     <li>",
"      Corticosteroid, Ophthalmic;",
"     </li>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F138817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic infection:",
"     </b>",
"     Ophthalmic ointment: Instill",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch ribbon to inside of lower lid every 3-4 hours until improvement occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Superficial dermal infection:",
"     </b>",
"     Topical: Apply sparingly 2-4 times/day. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F138824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/56/43908?source=see_link\">",
"      see \"Bacitracin, neomycin, polymyxin B, and hydrocortisone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F138818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: Bacitracin 400 units, neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neo-Polycin&trade; HC: Bacitracin 400 units, neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortisporin&reg;: Bacitracin 400 units, neomycin 3.5 mg, polymyxin B 5000 units, and hydrocortisone 10 mg per g (15 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Ophthalmic ointment",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F138808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of susceptible inflammatory conditions where bacterial infection (or risk of infection) is present",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F138827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. For additional information, see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic ointment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Delayed wound healing, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataracts, corneal thinning, glaucoma, irritation, keratitis (bacterial), intraocular pressure increase, optic nerve damage, scleral thinning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous:  Hypersensitivity (including anaphylaxis), secondary infection, sensitization to kanamycin, paromomycin, streptomycin, and gentamicin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Topical ointment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic:  Acneiform eruptions, allergic contact dermatitis, burning skin, dryness, folliculitis, hypertrichosis, hypopigmentation, irritation, maceration of skin, miliaria, ocular hypertension, perioral dermatitis, pruritus, skin atrophy, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ototoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity (including anaphylaxis), secondary infection, sensitization to karamycin, paromycin, streptomycin, and gentamicin",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F138811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bacitracin, neomycin, polymyxin B, hydrocortisone, or any component of the formulation; not for use in viral infections, fungal diseases, mycobacterial infections",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F138796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin sensitization: Neomycin may cause cutaneous sensitization. Symptoms of neomycin sensitization include itching, reddening, edema, and failure to heal. Discontinuation of product and avoidance of similar products should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Topical corticosteroids: Children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic ointment: Should never be directly introduced into the anterior chamber. May retard corneal healing. Prolonged use may result in ocular hypertension/glaucoma, corneal and scleral thinning, potentially resulting in perforation. Use with caution in glaucoma. Avoid use following ocular cataract surgery. Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F138825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acarbose: Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may enhance the therapeutic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Neomycin may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with topical corticosteroids in animal reproduction studies. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F138820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if systemic absorption following topical administration results in detectable quantities in human milk. Breast-feeding is not recommended by the manufacturer. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Cortisporin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 g): $92.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Neo-Polycin HC Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (3.5 g): $59.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F138804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If ophthalmic ointment is used &gt;10 days or in patients with glaucoma, monitor intraocular pressure (IOP).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F138812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cortisporin Topical Ointment (CA);",
"     </li>",
"     <li>",
"      Polybamycin (SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F138795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F138810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17413/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9059 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-9DBBEBA25B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17413=[""].join("\n");
var outline_f17_0_17413=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138815\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138816\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138829\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138817\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138824\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138818\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138806\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138792\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138808\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138827\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138811\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138796\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138825\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138800\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138802\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287174\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138820\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287176\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524348\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138804\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138812\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138795\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138810\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9059\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9059|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/53/30548?source=related_link\">",
"      Bacitracin, neomycin, polymyxin B, and hydrocortisone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/56/43908?source=related_link\">",
"      Bacitracin, neomycin, polymyxin B, and hydrocortisone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_0_17414="Spironolactone: Pediatric drug information";
var content_f17_0_17414=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Spironolactone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"    see \"Spironolactone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/27/19893?source=see_link\">",
"    see \"Spironolactone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactone&reg;;",
"     </li>",
"     <li>",
"      Novo-Spiroton;",
"     </li>",
"     <li>",
"      Teva-Spironolactone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Potassium Sparing",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Diuretic: 1-3 mg/kg/day divided every 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"      see \"Spironolactone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diuretic, hypertension: 1-3.3 mg/kg/day or 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-12 hours; not to exceed 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diagnosis of primary aldosteronism: 100-400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edema, hypokalemia: 25-200 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypertension (JNC 7): 25-50 mg/day divided once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heart failure, severe (NYHA class III-IV; with ACE inhibitor and a loop diuretic &plusmn; digoxin): 12.5-25 mg/day; maximum daily dose: 50 mg. If 25 mg once daily not tolerated, reduction to 25 mg every other day was the lowest maintenance dose possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diagnosis of primary aldosteronism: 100-400 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acne in women: 25-200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hirsutism in women: 50-200 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CHF: Patients with severe heart failure already using an ACE inhibitor and a loop diuretic &plusmn; digoxin: 12.5-25 mg/day, increase or reduce depending on individual response and evidence of hyperkalemia; maximum daily dose: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aldactone&reg;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aldactone&reg;: 50 mg, 100 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F222819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of edema associated with CHF, cirrhosis of the liver accompanied by edema or ascites, and nephrotic syndrome; treatment of essential hypertension, primary hyperaldosteronism, hypokalemia, and hirsutism; treatment of severe heart failure (NYHA class III-IV) to increase survival and reduce hospitalizations when used in addition to standard therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F222916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aldactone&reg; may be confused with Aldactazide&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aldactone: Brand name for spironolactone [U.S., Canada, multiple international markets], but also the brand name for potassium canrenoate [Austria, Czech Republic, Germany, Hungary, Poland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F222914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, drowsiness, fever, headache, lethargy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Drug rash with eosinophilia and systemic symptoms (DRESS), maculopapular or erythematous cutaneous eruptions, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, gynecomastia, hyperkalemia, impotence, irregular menses, postmenopausal bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Cramps, diarrhea, gastritis, gastric bleeding, nausea, ulceration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic/hepatocellular toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, renal dysfunction, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reaction, breast cancer",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to spironolactone or any component; renal failure, anuria, hyperkalemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant administration of potassium-sparing diuretics (eg, amiloride and triamterene) and ACE inhibitors or NSAIDs has been associated with severe hyperkalemia; may cause transient elevation of BUN, possibly due to a concentration effect; sustained elevations should be evaluated; monitor potassium levels closely; in CHF, potassium levels and renal function should be checked in 3 days and 1 week after beginning therapy, then every 2-4 weeks for 3-12 months, then every 3-6 months. Discontinue or interrupt therapy for serum potassium &gt;5 mEq/L or for serum creatinine &gt;4 mg/dL in patients with heart failure. Use with caution in patients with dehydration, hyponatremia, impaired renal clearance (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute) or hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Spironolactone has been shown to be tumorigenic in toxicity studies using 25-250 times the usual human dose in rats",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F222828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: Spironolactone may diminish the therapeutic effect of Abiraterone Acetate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Spironolactone may diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Spironolactone may increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drospirenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: Spironolactone may diminish the therapeutic effect of Mitotane.  Management: Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeutic failure of the mitotane.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Spironolactone may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrofurantoin: May enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1062354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss) and salt substitutes; avoid diets high in potassium",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F222846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however, doses used were less than or equal to equivalent doses in humans. The antiandrogen effects of spironolactone have been shown to cause feminization of the male fetus in animal studies. Two case reports did not demonstrate this effect in humans however, the authors caution that adequate data is lacking. Use of diuretics during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, sodium, and renal function",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with aldosterone for receptor sites in the distal renal tubules, increasing sodium chloride and water excretion while conserving potassium and hydrogen ions; may block the effect of aldosterone on arteriolar smooth muscle as well",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Breast milk to plasma ratio: 0.51-0.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 91% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to multiple metabolites, including canrenone (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spironolactone: 78-84 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canrenone: 13-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 1-3 hours (primarily as the active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urinary and biliary",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/27/19893?source=see_link\">",
"      see \"Spironolactone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F222840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made with tablets. Crush ten 25 mg tablets in a mortar and reduce to a fine powder. Add a small amount of purified water and soak for 5 minutes; add 50 mL 1.5% carboxymethylcellulose, 100 mL syrup NF, and mix to a uniform paste; mix while adding purified water in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     250 mL; transfer to a calibrated bottle, rinse mortar with purified water, and add quantity of purified water sufficient to make 250 mL. Label \"shake well\". Stable for 3 months at room temperature or refrigerated (Nahata, 1993).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 2.5 mg/mL oral suspension may be made with tablets. Crush twelve 25 mg tablets in a mortar and reduce to a fine powder. Add small portions of distilled water or glycerin and mix to a uniform paste; mix while adding cherry syrup to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with cherry syrup, and add quantity of cherry syrup sufficient to make 120 mL. Label \"shake well\" and \"refrigerate\". This method may also be used with twenty-four 25 mg tablets for a 5 mg/mL oral suspension. Both concentrations are stable for 28 days refrigerated (Mathur, 1989).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 25 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;. Crush one-hundred-twenty 25 mg tablets in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Store in amber bottles; label \"shake well\" and \"refrigerate\". Stable for 60 days refrigerated (Allen, 1996).",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and  Erickson MA 3rd, \"Stability of Ketoconazole, Metolazone, Metronidazole, Procainamide Hydrochloride, and Spironolactone in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(17):2073-8.",
"     <span class=\"pubmed-id\">",
"      8870895",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Mathur LK and Wickman A, \"Stability of Extemporaneously Compounded Spironolactone Suspensions,\"",
"     <i>",
"      Am J Hosp Pharm",
"     </i>",
"     , 1989, 46(10):2040-2.",
"     <span class=\"pubmed-id\">",
"      2816959",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Nahata MC, Morosco RS, and Hipple TF, \"Stability of Spironolactone in an Extemporaneously Prepared Suspension at Two Temperatures,\"",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 1993, 27(10):1198-9.",
"     <span class=\"pubmed-id\">",
"      8251687",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17414/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, \"ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure),\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 46(6):1116-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17414/abstract-text/16168273/pubmed\" id=\"16168273\" target=\"_blank\">",
"        16168273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juurlink DN, Mamdani MM, Lee DS, et al, \"Rates of Hyperkalemia After Publication of the Randomized Aldactone Evaluation Study,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(6):543-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17414/abstract-text/15295047/pubmed\" id=\"15295047\" target=\"_blank\">",
"        15295047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17414/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Zannad F, Remme WJ, et al, \"The Effect of Spironolactone on Morbidity and Mortality in Patients With Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(10):709-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17414/abstract-text/10471456/pubmed\" id=\"10471456\" target=\"_blank\">",
"        10471456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van der Vorst MM, Kist JE, van der Heijden AJ, et al, \"Diuretics in Pediatrics: Current Knowledge and Future Prospects,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2006, 8(4):245-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17414/abstract-text/16898855/pubmed\" id=\"16898855\" target=\"_blank\">",
"        16898855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12803 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-3DC0084E0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17414=[""].join("\n");
var outline_f17_0_17414=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709416\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222861\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222862\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062344\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445113\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062337\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222819\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062348\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062347\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222916\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222914\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062352\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062336\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062335\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300079\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222828\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062354\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222831\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222846\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062343\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062334\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062351\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062342\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222840\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12803|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=related_link\">",
"      Spironolactone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/27/19893?source=related_link\">",
"      Spironolactone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_0_17415="Ceftazidime: Drug information";
var content_f17_0_17415=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ceftazidime: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/6/34915?source=see_link\">",
"    see \"Ceftazidime: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"    see \"Ceftazidime: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F147933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fortaz&reg;;",
"     </li>",
"     <li>",
"      Tazicef&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F147934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ceftazidime For Injection;",
"     </li>",
"     <li>",
"      Fortaz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F147980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (Third Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F147937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bacterial arthritis (gram negative bacilli):",
"     </b>",
"     I.V.: 1-2 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bone and joint infections:",
"     </b>",
"     I.V.: 2 g every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cystic fibrosis, lung infection caused by",
"     </b>",
"     <b>",
"      <i>",
"       Pseudomonas",
"      </i>",
"     </b>",
"     <b>",
"      spp:",
"     </b>",
"     I.V.: 30-50 mg/kg/dose every 8 hours (maximum: 6 g daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Endophthalmitis, bacterial (unlabeled use):",
"     </b>",
"     Intravitreal: 2.25 mg/0.1 mL NS in combination with vancomycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intra-abdominal infection, severe (in combination with metronidazole):",
"     </b>",
"     I.V.: 2 g every 8  hours for 4-7 days (provided source controlled). Not recommended for hospital-acquired intra-abdominal infections (IAI) associated with multidrug-resistant gram negative organisms or in mild-to-moderate community-acquired IAIs due to risk of toxicity and the development of resistant organisms (Solomkin, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Melioidosis:",
"     </b>",
"     I.V.: 40 mg/kg/dose every 8 hours for 10 days, followed by oral therapy with doxycycline or TMP/SMX",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Otitis externa:",
"     </b>",
"     I.V.: 2 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Peritonitis (CAPD):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Anuric, intermittent:",
"     </i>",
"     1-1.5 g daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Anuric, continuous (per liter exchange):",
"     </i>",
"     Loading dose: 250 mg; maintenance dose: 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pneumonia:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Uncomplicated:",
"     </i>",
"     500 mg to 1 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Complicated or severe:",
"     </i>",
"     2 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prosthetic joint infection,",
"     </b>",
"     <b>",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"     </b>",
"     <b>",
"      (alternative to cefepime or meropenem):",
"     </b>",
"     I.V.: 2 g every 8 hours for 4-6 weeks (consider addition of an aminoglycoside) (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin and soft tissue infections:",
"     </b>",
"     I.V., I.M.: 500 mg to 1 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Severe infections, including meningitis, complicated pneumonia, endophthalmitis, CNS infection, osteomyelitis, gynecological, skin and soft tissue:",
"     </b>",
"     I.V.: 2 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infections:",
"     </b>",
"     I.V., I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Uncomplicated:",
"     </i>",
"     250 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Complicated:",
"     </i>",
"     500 mg every 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F147959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"      see \"Ceftazidime: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Susceptible infections: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 1 month to 12 years: 30-50 mg/kg/dose every 8 hours; maximum dose: 6 g/day (higher doses reserved for immunocompromised patients, cystic fibrosis, or meningitis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F147938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V.: Dosage should be based on renal function with a dosing interval not more frequent then every 12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F147939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 48-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (50% to 100%): 500 mg to 1 g every 24 hours",
"     <b>",
"      or",
"     </b>",
"     1-2 g every 48-72 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of  3 times per week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Loading dose of 1 g, followed by 500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005):  Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH: Loading dose of 2 g followed by 1-2 g every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHD/CVVHDF: Loading dose of 2 g followed by either 1 g every 8 hours",
"     <b>",
"      or",
"     </b>",
"     2 g every 12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage of 1 g every 8 hours results in similar steady-state concentrations as 2 g every 12 hours and is more cost effective. Dosage of 2 g every 8 hours may be needed for gram-negative rods with MIC &ge;4 mg/L (Heintz, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For patients receiving CVVHDF, some recommend giving a loading dose of 2 g followed by 3 g over 24 hours as a continuous I.V. infusion to maintain concentrations &ge;4 times the MIC for susceptible pathogens (Heintz, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic solution, as sodium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fortaz&reg;: 1 g (50 mL); 2 g (50 mL) [contains sodium ~54 mg (2.3 mEq)/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 2 g, 6 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fortaz&reg;: 500 mg, 1 g, 2 g, 6 g [contains sodium ~54 mg (2.3 mEq)/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tazicef&reg;: 1 g, 2 g, 6 g [contains sodium ~54 mg (2.3 mEq)/g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F147915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Any carbon dioxide bubbles that may be present in the withdrawn solution should be expelled prior to injection. Administer around-the-clock to promote less variation in peak and trough serum levels. Ceftazidime can be administered deep I.M. into large mass muscle, IVP over 3-5 minutes, or I.V. intermittent infusion over 15-30 minutes. Do not admix with aminoglycosides in same bottle/bag. Final concentration for I.V. administration should not exceed 100 mg/mL.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F147985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS, Ringer's injection, sterile water for injection, in peritoneal dialysis solutions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, amikacin, anidulafungin, aztreonam, bivalirudin, ciprofloxacin, daptomycin, dexmedetomidine, diltiazem, docetaxel, dopamine, enalaprilat, epinephrine, esmolol, etoposide phosphate, famotidine, fenoldopam, filgrastim, fludarabine, foscarnet, furosemide, gallium nitrate, gemcitabine, gentamicin, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, insulin (regular), ketamine, labetalol, linezolid, melphalan, meperidine, methylprednisolone sodium succinate, milrinone, morphine, ondansetron, paclitaxel, ranitidine, remifentanil, sufentanil, tacrolimus, telavancin, teniposide, thiotepa, tigecycline, tobramycin, valproate sodium, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acetylcysteine, amiodarone, amphotericin B cholesteryl sulfate complex, amsacrine, azithromycin, caspofungin, dobutamine, doxorubicin liposome, erythromycin lactobionate, idarubicin, midazolam, pantoprazole, pemetrexed, pentamidine, phenytoin, warfarin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aminopylline, cisatracurium, doxapram, drotrecogin alfa, fluconazole, nicardipine, propofol, sargramostim, theophylline, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate, hydromorphone.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F147914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of documented susceptible",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     infection and infections due to other susceptible aerobic gram-negative organisms; empiric therapy of a febrile, granulocytopenic patient",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4805442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bacterial endophthalmitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F147987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CefTAZidime may be confused with ceFAZolin, cefepime, cefoTEtan, cefOXitin,  cefTRIAXone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ceptaz&reg; may be confused with Septra&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tazicef&reg; may be confused with Tazidime&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ceftim [Portugual] and Ceftime [Thailand] brand names for ceftazidime may be confused with Ceftin brand name for cefuroxime [U.S., Canada]; Cefiton brand name for cefixime [Portugal]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F147978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, asterixis, BUN increased, candidiasis, creatinine increased, dizziness, encephalopathy, eosinophilia, erythema multiforme, fever, headache, hemolytic anemia, hyperbilirubinemia, jaundice, leukopenia, myoclonus, nausea, neuromuscular excitability, paresthesia, phlebitis, pruritus, pseudomembranous colitis, rash, Stevens-Johnson syndrome, thrombocytosis, toxic epidermal necrolysis, transaminases increased, vaginitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Agranulocytosis, aplastic anemia, cholestasis, colitis, hemolytic anemia, hemorrhage, interstitial nephritis, pancytopenia, prolonged PT, renal dysfunction, seizure, serum-sickness reactions, superinfection, toxic nephropathy, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F147918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ceftazidime, any component of the formulation, or other cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F147899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5951787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Ceftazidime crosses the placenta and reaches the cord serum and amniotic fluid. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins. Maternal peak serum concentration is unchanged in the first trimester. After the first trimester, serum concentrations decrease by approximately 50% of those in nonpregnant patients. Renal clearance is increased during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F147945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F147921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Very small amounts of ceftazidime are excreted in breast milk. The manufacturer recommends that caution be exercised when administering ceftazidime to nursing women. Ceftazidime in not absorbed when given orally; therefore, any medication that is distributed to human milk should not result in systemic concentrations in the nursing infant. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F147922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fortaz in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/50 mL 5% (50 mL): $16.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g/50 mL 5% (50 mL): $31.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tazicef Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 gm/50 mL (50 mL): $16.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CefTAZidime and Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 gm/50 mL (1): $12.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 gm/50 mL (1): $18.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CefTAZidime Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $5.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $12.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 g (1): $35.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Fortaz Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $14.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $28.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 g (1): $82.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $7.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Fortaz Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $14.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $28.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Tazicef Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $3.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $10.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 g (1): $23.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Tazicef Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $4.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $11.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F147909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F147923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Baxidyme (PH);",
"     </li>",
"     <li>",
"      Biotum (PL);",
"     </li>",
"     <li>",
"      Caltum (ID);",
"     </li>",
"     <li>",
"      Cef-H (MY);",
"     </li>",
"     <li>",
"      Cefadime (TW);",
"     </li>",
"     <li>",
"      Cefatum (MY);",
"     </li>",
"     <li>",
"      Cefazime (SG);",
"     </li>",
"     <li>",
"      Cefortam (PT);",
"     </li>",
"     <li>",
"      Cefpiran (PE);",
"     </li>",
"     <li>",
"      Ceftidin (IN);",
"     </li>",
"     <li>",
"      Ceftim (IT, PT);",
"     </li>",
"     <li>",
"      Ceftum (ID);",
"     </li>",
"     <li>",
"      Cetazine (TW);",
"     </li>",
"     <li>",
"      Cetazum (ID);",
"     </li>",
"     <li>",
"      Dimcef (KP);",
"     </li>",
"     <li>",
"      Dimzef (PH);",
"     </li>",
"     <li>",
"      Extimon (ID);",
"     </li>",
"     <li>",
"      Fivtum (PH);",
"     </li>",
"     <li>",
"      Fortam (CH, ES, UY);",
"     </li>",
"     <li>",
"      Fortaz (BR);",
"     </li>",
"     <li>",
"      Fortum (AE, AR, AT, AU, BB, BF, BG, BH, BJ, BM, BS, BZ, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ET, FR, GB, GH, GM, GN, GT, GY, HK, HN, HU, IE, IL, IN, IQ, IR, JM, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PR, PY, QA, RU, SA, SC, SD, SE, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Fortum Pro (HN);",
"     </li>",
"     <li>",
"      Fortumset (FR);",
"     </li>",
"     <li>",
"      Forzid (PH);",
"     </li>",
"     <li>",
"      Ftazidime (GR);",
"     </li>",
"     <li>",
"      Glazidim (BE, FI, IT, LU);",
"     </li>",
"     <li>",
"      Izadima (EC);",
"     </li>",
"     <li>",
"      Kefadim (BF, BJ, BR, CI, ET, GH, GM, GN, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, PK, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Kefazim (AT);",
"     </li>",
"     <li>",
"      Kefzim (CN);",
"     </li>",
"     <li>",
"      Lacedim (ID);",
"     </li>",
"     <li>",
"      Lemoxol (NZ);",
"     </li>",
"     <li>",
"      Megacef (PH);",
"     </li>",
"     <li>",
"      Mirocef (HR);",
"     </li>",
"     <li>",
"      Parzidim (SG);",
"     </li>",
"     <li>",
"      Pharodime (ID);",
"     </li>",
"     <li>",
"      Romacef (PH);",
"     </li>",
"     <li>",
"      Septax (IL);",
"     </li>",
"     <li>",
"      Solvetan (GR);",
"     </li>",
"     <li>",
"      Spectrum (IT);",
"     </li>",
"     <li>",
"      Starcef (IT);",
"     </li>",
"     <li>",
"      Tagal (MX);",
"     </li>",
"     <li>",
"      Tazicef (KP, PH);",
"     </li>",
"     <li>",
"      Tazidan (PH);",
"     </li>",
"     <li>",
"      Tazidem (PH);",
"     </li>",
"     <li>",
"      Tazime (CL, KP, SG);",
"     </li>",
"     <li>",
"      Thidim (ID);",
"     </li>",
"     <li>",
"      Tinacef (AR);",
"     </li>",
"     <li>",
"      Yadim (HK);",
"     </li>",
"     <li>",
"      Zadim (PH);",
"     </li>",
"     <li>",
"      Zadolina (MX);",
"     </li>",
"     <li>",
"      Zeptrigen (PH);",
"     </li>",
"     <li>",
"      Zibac (ID);",
"     </li>",
"     <li>",
"      Zytaz (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F147898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F147917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely throughout the body including bone, bile, skin, CSF (higher concentrations achieved when meninges are inflamed), endometrium, heart, pleural and lymphatic fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 17%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1-2 hours, prolonged with renal impairment; Neonates &lt;23 days: 2.2-4.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80% to 90% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society and Infectious Diseases Society of America, &ldquo;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 171(4):388-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/15699079/pubmed\" id=\"15699079\" target=\"_blank\">",
"        15699079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies SP, Lacey LF, Kox WJ, et al, &ldquo;Pharmacokinetics of Cefuroxime and Ceftazidime in Patients With Acute Renal Failure Treated by Continuous Arteriovenous Haemodialysis,&rdquo;",
"      <i>",
"       Nephrology, Dialysis, Transplantation",
"      </i>",
"      , 1991, 6(120):971-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein NC and Cunha BA, &ldquo;Third-Generation Cephalosporins,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 1995, 79(4):705-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/7791418/pubmed\" id=\"7791418\" target=\"_blank\">",
"        7791418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(2):187-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/10069359/pubmed\" id=\"10069359\" target=\"_blank\">",
"        10069359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCracken GH Jr, Threlkeld N, and Thomas ML, &ldquo;Pharmacokinetics of Ceftazidime in Newborn Infants,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1984, 26(4):583-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/6393862/pubmed\" id=\"6393862\" target=\"_blank\">",
"        6393862",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rains CP, Bryson HM, and Peters DH, &ldquo;Ceftazidime. An Update of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Efficacy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1995, 49(4):577-617.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/7789291/pubmed\" id=\"7789291\" target=\"_blank\">",
"        7789291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Results of the Endophthalmitis Vitrectomy Study. A Randomized Trial of Immediate Vitrectomy and of Intravenous Antibiotics for the Treatment of Postoperative Bacterial Endophthalmitis. Endophthalmitis Vitrectomy Study Group,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1995, 113(12):1479-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/7487614/pubmed\" id=\"7487614\" target=\"_blank\">",
"        7487614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson DG, Cookson TL, and Frisafe JA, &ldquo;Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(12):985-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/3428165/pubmed\" id=\"3428165\" target=\"_blank\">",
"        3428165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roth DB and Flynn HW Jr, &ldquo;Antibiotic Selection in the Treatment of Endophthalmitis: The Significance of Drug Combinations and Synergy,&rdquo;",
"      <i>",
"       Surv Ophthalmol",
"      </i>",
"      , 1997, 41(5):395-401.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/9163836/pubmed\" id=\"9163836\" target=\"_blank\">",
"        9163836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sirgo MA and Norris S, &ldquo;Ceftazidime in the Elderly: Appropriateness of Twice-Daily Dosing,&rdquo;",
"      <i>",
"       DICP Ann Pharmacother",
"      </i>",
"      , 1991, 25(3):284-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slaker RA and Danielson B, &ldquo;Neurotoxicity Associated With Ceftazidime Therapy in Geriatric Patients With Renal Dysfunction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1991, 11(4):351-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/1923920/pubmed\" id=\"1923920\" target=\"_blank\">",
"        1923920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stea S, Bachelor T, Cooper M, et al, &ldquo;Disposition and Bioavailability of Ceftazidime After Intraperitoneal Administration in Patients Receiving Continuous Ambulatory Peritoneal Dialysis,&rdquo;",
"      <i>",
"       J Am Soc Nephrol",
"      </i>",
"      , 1996, 7(11):2399-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/8959631/pubmed\" id=\"8959631\" target=\"_blank\">",
"        8959631",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vlasses PH, Bastion WA, Behal R, et al, &ldquo;Ceftazidime Dosing in the Elderly: Economic Implications,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1993, 27(7-8):967-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/8364284/pubmed\" id=\"8364284\" target=\"_blank\">",
"        8364284",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(15):1736-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/0/17415/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9226 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17415=[""].join("\n");
var outline_f17_0_17415=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147933\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147934\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147980\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147937\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147959\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147938\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147939\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682549\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147911\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147895\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147915\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147985\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147914\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4805442\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147987\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147978\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147918\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147899\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298996\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147904\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147907\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951787\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147945\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147921\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147922\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323051\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147909\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147923\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147898\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147917\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9226\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9226|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/6/34915?source=related_link\">",
"      Ceftazidime: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=related_link\">",
"      Ceftazidime: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_0_17416="Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children";
var content_f17_0_17416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/0/17416/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17416/contributors\">",
"     Paul Krogstad, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/0/17416/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17416/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/0/17416/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17416/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/0/17416/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis refers to an infection of bone. It is usually bacterial in origin. Microorganisms can be introduced into bone in three ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematogenous delivery",
"     </li>",
"     <li>",
"      Direct inoculation (usually traumatic, but also surgical)",
"     </li>",
"     <li>",
"      Local invasion from a contiguous infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, acute osteomyelitis is generally hematogenous in origin. Unique anatomic characteristics of the growing skeleton also affect the site of infection, pathogenesis, and clinical features of the disease on account of hematogenous spread.",
"   </p>",
"   <p>",
"    Nonhematogenous osteomyelitis is much less common in children. Risk factors for nonhematogenous osteomyelitis include open fractures that require surgical reduction, the presence of implanted orthopedic hardware (such as pins or screws), and puncture wounds. Infection also can spread to bone from contiguous sites such as sinuses or teeth.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children. Clinical features, evaluation, diagnosis, and treatment of hematogenous osteomyelitis in children are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24730?source=see_link\">",
"     \"Treatment of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the incidence of osteomyelitis have varied from as low as 1 per 20,000 adolescents in New Zealand to as high as 1 per 1000 Australian aboriginals. In one report, the incidence of osteomyelitis among children in Scotland was 3 per 100,000 and appeared to be declining [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, review of discharge data from a single children's hospital in the United States found that the incidence of osteoarticular infections (osteomyelitis and septic arthritis) increased from 2.6 to 6.0 per 1000 admissions between 2000 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of hematogenous osteomyelitis is highest in the first two decades of life. Among children, it occurs more often in those who are younger. At least one-quarter of patients are younger than two years of age, and more than one-half are younger than five years of age. Boys are affected about twice as often as girls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for hematogenous osteomyelitis in children include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sickle cell disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18506?source=see_link&amp;anchor=H12#H12\">",
"       \"Bone and joint complications in sickle cell disease\", section on 'Osteomyelitis and septic arthritis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Immunodeficiency disorders, such as chronic granulomatous disease",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Minor trauma coincident with bacteremia",
"     </li>",
"     <li>",
"      Indwelling vascular catheters",
"     </li>",
"     <li>",
"      Chronic hemodialysis vascular access",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Pathogens in abnormal hosts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among neonates, hematogenous osteomyelitis is uncommon and occurs most often in critically ill newborns. In these patients, risk factors include prematurity, skin infection, a central venous catheter, or a complicated delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/5\">",
"     5",
"    </a>",
"    ]. This was illustrated in a report of a series of 30 neonates with osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/6\">",
"     6",
"    </a>",
"    ]. In this group, 17 were premature infants requiring artificial ventilation, and four were full-term infants who also were patients in the neonatal intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SITE OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematogenous osteomyelitis generally occurs at only one site. Tubular bones are affected more frequently than nontubular (flat) bones or spine (",
"    <a class=\"graphic graphic_figure graphicRef61415 \" href=\"UTD.htm?34/34/35364\">",
"     figure 1",
"    </a>",
"    ). Multifocal infection is more common in critically ill neonates and in children with disease caused by community-associated methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tubular bones",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 80 percent of cases of hematogenous osteomyelitis occur in tubular bones, most often in the rapidly growing metaphyses of long bones [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/9\">",
"     9",
"    </a>",
"    ]. More than 50 percent of infections in tubular bones involve the femur, tibia, or fibula [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/3,4,9\">",
"     3,4,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nontubular bones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection in nontubular, or flat, bones usually occurs in the calcaneus and pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In a review of 257 cases of pelvic osteomyelitis, the ilium was most frequently involved (47 percent), followed by the ischium (23 percent) and the pubis (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/10\">",
"     10",
"    </a>",
"    ]. Involvement of the sacroiliac joint may also be observed in approximately 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections of the spine can involve either the intervertebral disc or the vertebral bodies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discitis occurs almost exclusively in the lumbar regions. The majority of affected children are younger than five years of age. Treatment with antibiotics is generally recommended, even though bacteria are not always identified. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=see_link&amp;anchor=H14#H14\">",
"       \"Back pain in children and adolescents: Overview of causes\", section on 'Discitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The vertebrae are involved in 1 to 2 percent of cases of osteomyelitis in children [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Patients usually are older than 8 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, hematogenous osteomyelitis begins with bacterial deposition in the metaphysis (",
"    <a class=\"graphic graphic_figure graphicRef65719 \" href=\"UTD.htm?0/47/758\">",
"     figure 2",
"    </a>",
"    ). The mechanism of deposition is unclear, although some evidence suggests that endothelial cells may permit microbial passage. Electron microscopy of the capillary loops of the metaphyseal vessels reveals that the distal vessels are composed of a single layer of discontinuous endothelium. Tracer particles can escape through this endothelial layer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. It is therefore possible that bacteria also pass through these gaps during an episode of bacteremia, thereby initiating osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, trauma or emboli lead to occlusion of the slow-flowing sinusoidal vessels, further establishing a nidus for infection. The growth of microorganisms is facilitated because metaphyseal capillaries lack phagocytic lining cells, and the sinusoidal veins contain functionally inactive phagocytic cells.",
"   </p>",
"   <p>",
"    Cellulitis develops in the bone marrow from foci of infection in the metaphysis. In the absence of therapy, necrosis of cortical bone and marrow occurs. The exudate under pressure is forced through the Haversian systems and Volkmann canals and into the cortex of the bone.",
"   </p>",
"   <p>",
"    Subacute and chronic infection may subsequently develop [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    .) Subacute infection is classically characterized by the formation of an intraosseous abscess or Brodie abscess. In this process, a central area of suppuration and necrosis is contained and encapsulated by granulation tissue (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87102 \" href=\"UTD.htm?35/54/36709\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/17\">",
"     17",
"    </a>",
"    ]. Extension of the abscess into the adjacent medullary bone or epiphysis can occur.",
"   </p>",
"   <p>",
"    Bone necrosis continues if treatment is inadequate or not given. Areas of nonviable bone that develop are called sequestra. An involucrum, a sheath of periosteal bone, may form around a sequestrum.",
"   </p>",
"   <p>",
"    With children, this complex process is influenced by characteristics of the growing skeleton. Thus, the pathogenesis of hematogenous osteomyelitis varies, in part, with the child's age (",
"    <a class=\"graphic graphic_figure graphicRef50672 \" href=\"UTD.htm?42/14/43237\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Newborns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following features of the newborn skeleton affect the pathogenesis of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thin cortex and loosely applied periosteum are poor barriers to the spread of infection. Infection can therefore spread along the subperiosteal space and break through the thin metaphyseal cortex into the surrounding soft tissue.",
"     </li>",
"     <li>",
"      Nutrient metaphyseal capillaries perforate the epiphyseal growth plate, particularly in the hip, shoulder, and knee. Infection can thus involve the epiphysis and joint surface.",
"     </li>",
"     <li>",
"      The capsule of the diarthrodial joints frequently extends to, or is slightly distal to, the epiphyseal plate, allowing infection to invade the joint space. As a consequence, some cases of osteomyelitis are associated with septic arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link&amp;anchor=H4#H4\">",
"       \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Older infants and toddlers",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the skeleton matures, the following changes are noted among older infants and toddlers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cortex becomes thicker and the periosteum slightly more dense. Thus, although infection rarely spreads to the soft tissues of the extremity, subperiosteal abscess and contiguous edema readily develop. Subperiosteal purulence is usually at the metaphysis, the area in which the cortex is the thinnest [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Metaphyseal capillaries atrophy as the epiphysis becomes ossified and a distinct physeal plate is formed. This process begins as early as eight months of age and is usually complete by 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/20\">",
"       20",
"      </a>",
"      ]. As a result, spread of infection into the joint is unusual in older infants unless the metaphysis is intracapsular, as occurs with the humerus in the shoulder and the femur in the hip.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These anatomic features explain reports citing a higher incidence of simultaneous septic arthritis and osteomyelitis in younger infants. However, this association has not been uniformly noted. In one series of 66 children with hematogenous osteomyelitis, there was no difference in the incidence of adjacent joint involvement between patients &lt;18 months of age and older children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children and adolescents (4 to 16 years of age), the metaphyseal cortex is considerably thicker, with a dense, fibrous periosteum. The pathogenesis of infection is the same in this age group as in infants and toddlers; however, the infection is more contained and rarely ruptures and spreads to the outer cortical lamellae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vertebral osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebral infections can involve either the intervertebral disc or the vertebral body. The pathogenesis of infection at these sites differs from the process in other locations.",
"   </p>",
"   <p>",
"    The blood supply to the intervertebral disc is rich in young children, being derived from both periosteal vessels and contiguous vertebral bodies. The vessels from adjacent vertebrae begin to atrophy in the first year of life and are obliterated completely by 10 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This may account for the observation that discitis is more common in younger children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to discitis, the pathogenesis of vertebral osteomyelitis may be related to sluggish blood flow and thrombosis in the vertebral veins, in conjunction with bacterial seeding. The venous drainage of the vertebral bodies and the pathogenesis of infection in this location are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=see_link&amp;anchor=H3#H3\">",
"     \"Vertebral osteomyelitis and discitis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteria, principally",
"    <em>",
"     S. aureus",
"    </em>",
"    , cause the vast majority of cases of acute osteomyelitis in children. A single organism is responsible for most infections. However, no pathogen is isolated in as many as 50 percent of cases, which are most commonly believed to be the result of",
"    <em>",
"     S. aureus",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/11,24-26\">",
"     11,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     S. aureus",
"    </em>",
"    is recovered in more than half of cases of osteomyelitis in both infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/4,11,24,25\">",
"     4,11,24,25",
"    </a>",
"    ]. The high frequency of",
"    <em>",
"     S. aureus",
"    </em>",
"    may be related to a number of extracellular and cell-associated virulence factors that promote bacterial adherence, resistance to host defense mechanisms, and proteolytic activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of osteomyelitis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA) has emerged as a common etiologic agent in musculoskeletal infections in children. This was illustrated in a retrospective review of 59 children with",
"    <em>",
"     S. aureus",
"    </em>",
"    osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/7\">",
"     7",
"    </a>",
"    ]. CA-MRSA was identified from blood or bone cultures in 31 patients (53 percent). The gene encoding Panton-Valentine leukocidin (PVL) was more frequent in MRSA isolates (87 versus 24 percent in methicillin-susceptible isolates). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'CA-MRSA strains'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PVL is an exotoxin associated with CA-MRSA and may be related to the propensity of this organism to cause skin and soft tissue infections, as well as hemorrhagic necrotizing pneumonia. In the series described in the preceding paragraph, all children who developed complications had PVL-positive isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/7\">",
"     7",
"    </a>",
"    ]. Additional reports also suggest that multifocal disease, local abscess formation, venous thrombosis, and a greater systemic inflammatory response are more common with PVL-positive isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/8,27-30\">",
"     8,27-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'CA-MRSA strains'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bacteria other than staphylococci",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group B streptococcus and",
"    <em>",
"     Escherichia coli",
"    </em>",
"    in neonates, and group A streptococcus in older infants and children, are also significant causes of hematogenous osteomyelitis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/31\">",
"     31",
"    </a>",
"    ]. Newborns with group B streptococcal osteomyelitis are usually two to four weeks of age. Generally, there is no recognized preceding infection, and a single bone is involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link&amp;anchor=H19#H19\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Other focal infection'",
"    </a>",
"    .)",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    has been most commonly seen in children younger than 24 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/32\">",
"     32",
"    </a>",
"    ]. Routine immunization during infancy with conjugated pneumococcal vaccines is likely to reduce the frequency of pneumococcal osteomyelitis.",
"   </p>",
"   <p>",
"    <em>",
"     Kingella kingae",
"    </em>",
"    , a gram-negative organism present in oral flora, is being increasingly identified as a cause of osteomyelitis in children younger than three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/33\">",
"     33",
"    </a>",
"    ]. It is a fastidious organism that is difficult to isolate by conventional culture techniques. Inoculation of specimens into blood culture vials has increased the yield of this organism. Molecular diagnostic methods, such as polymerase chain reaction (PCR) amplification, have been developed that may help identify more cases of osteomyelitis caused by",
"    <em>",
"     K. kingae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of skeletal infections caused by",
"    <em>",
"     K. kingae",
"    </em>",
"    was described in a cluster of cases in children attending a day care center [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/36\">",
"     36",
"    </a>",
"    ]. Within a one-week period, three children aged 17 to 21 months attending the same classroom developed hematogenous osteomyelitis and septic arthritis. Child-to-child transmission of the organism was likely because the prevalence of nasal carriage was high in the classroom where the cases occurred (45 percent compared with 7 percent in children attending other classrooms), and isolates from the confirmed cases and the carriers had identical patterns on pulse field gel electrophoresis. In a study using real-time PCR to detect",
"    <em>",
"     K. kingae",
"    </em>",
"    , the sternum was the most common site of osteomyelitis caused by this pathogen (five of seven cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteomyelitis resulting from",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    is now rare. However, it had been an important cause of hematogenous osteomyelitis prior to routine vaccination of children against",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other bacterial pathogens include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       Brucella",
"      </em>",
"      species can produce abscesses in the vertebral bodies or long bones, although bone involvement is not a striking feature of the disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of brucellosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <em>",
"       Mycobacterium tuberculosis",
"      </em>",
"      can cause hematogenous osteomyelitis in children and is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"       \"Skeletal tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cat scratch disease caused by",
"      <em>",
"       Bartonella henselae",
"      </em>",
"      is associated with osteomyelitis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. In a review of 47 cases of",
"      <em>",
"       B. henselae",
"      </em>",
"      osteomyelitis, the vertebral column and girdle were the most frequent sites of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=see_link\">",
"       \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fungus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidiomycosis, which is common in the southwestern United States, can cause infection in cancellous bone such as vertebral bodies, distal tubular bones, and the skull [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/41\">",
"     41",
"    </a>",
"    ]. Infection in multiple sites can occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=see_link\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone disease caused by aspergillus has been described in immunocompetent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/42\">",
"     42",
"    </a>",
"    ]. Actinomyces may cause infection in facial bones or vertebral bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Polymicrobial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymicrobial infection is unusual in children with acute osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/3\">",
"     3",
"    </a>",
"    ]. Isolation of multiple bacteria from bone generally occurs with spread from a contiguous infectious focus, usually from the skull, face, hands, or feet. Distal extremities that are compromised by vascular insufficiency or are immobile, as in patients with paraplegia, spina bifida, or following trauma such as lawn mower injuries, can be sites of polymicrobial osteomyelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pathogens in abnormal hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with sickle cell disease (SCD), hematogenous osteomyelitis is most often caused by Salmonella or other gram-negative organisms, such as",
"    <em>",
"     E. coli",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17416/abstract/44-51\">",
"     44-51",
"    </a>",
"    ].",
"    <em>",
"     S. aureus",
"    </em>",
"    , the most common cause of osteomyelitis in normal hosts, probably accounts for only one-fourth of all cases in SCD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18506?source=see_link\">",
"     \"Bone and joint complications in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with chronic granulomatous disease most often develop osteomyelitis caused by",
"    <em>",
"     Serratia",
"    </em>",
"    and",
"    <em>",
"     Aspergillus",
"    </em>",
"    species. Osteomyelitis is less often attributed to staphylococci,",
"    <em>",
"     Pseudomonas",
"    </em>",
"    ,",
"    <em>",
"     Burkholderia",
"    </em>",
"    ,",
"    <em>",
"     Nocardia",
"    </em>",
"    , and other bacterial and fungal species. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteomyelitis in patients with human immunodeficiency virus infection is most commonly caused by",
"    <em>",
"     S. aureus",
"    </em>",
"    . Other organisms that have been recovered in individual cases include",
"    <em>",
"     E. coli",
"    </em>",
"    ,",
"    <em>",
"     Salmonella enteritidis",
"    </em>",
"    ,",
"    <em>",
"     Cryptococcus neoformans",
"    </em>",
"    ,",
"    <em>",
"     Mycobacterium kansasii",
"    </em>",
"    , and",
"    <em>",
"     Histoplasma capsulatum",
"    </em>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, acute osteomyelitis is primarily hematogenous in origin. Epidemiologic features of the illness include the following (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estimates of the incidence of osteomyelitis vary widely, with precise information regarding the incidence in the United States being unknown. Hematogenous osteomyelitis occurs most commonly in children younger than five years. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for infections include critically ill neonates who are premature, have had skin infections, or have had a complicated delivery. Other patients at risk are those with a hemoglobinopathy or who are immunocompromised. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of hematogenous osteomyelitis is a complex process that is influenced by characteristics of the growing skeleton. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newborn bone has a thin cortex and loosely applied periosteum that provide poor barriers to the spread of infection. In addition, the metaphyseal blood supply, which crosses the epiphyseal growth plate, and the capsule of the diarthrodial joints, which often includes the epiphysis, expose the epiphysis and the joint space to infection. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Newborns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In older infants, toddlers, and children, the cortex of the bone is thicker, the periosteum is denser, and metaphyseal capillaries atrophy. Thus, infection becomes more localized. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Older infants and toddlers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Children and adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given that the blood supply to the intervertebral disc is rich in young children, discitis occurs more often in younger children, in comparison to vertebral osteomyelitis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vertebral osteomyelitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacteria cause the vast majority of cases of acute hematogenous osteomyelitis in children. However, no pathogen is isolated in about half of all cases. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      is the most common organism recovered. Community-associated methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      has emerged as a significant pathogen and may be associated with more complex disease. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Staphylococcus aureus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional bacterial pathogens include group A and B streptococcus,",
"      <em>",
"       Escherichia coli",
"      </em>",
"      ,",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      , and",
"      <em>",
"       Kingella kingae",
"      </em>",
"      . Osteomyelitis resulting from",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      is now rare. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Bacteria other than staphylococci'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/1\">",
"      Blyth MJ, Kincaid R, Craigen MA, Bennet GC. The changing epidemiology of acute and subacute haematogenous osteomyelitis in children. J Bone Joint Surg Br 2001; 83:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/2\">",
"      Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus. J Pediatr Orthop 2006; 26:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/3\">",
"      Nelson JD. Acute osteomyelitis in children. Infect Dis Clin North Am 1990; 4:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/4\">",
"      Goergens ED, McEvoy A, Watson M, Barrett IR. Acute osteomyelitis and septic arthritis in children. J Paediatr Child Health 2005; 41:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/5\">",
"      Knudsen CJ, Hoffman EB. Neonatal osteomyelitis. J Bone Joint Surg Br 1990; 72:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/6\">",
"      Wong M, Isaacs D, Howman-Giles R, Uren R. Clinical and diagnostic features of osteomyelitis occurring in the first three months of life. Pediatr Infect Dis J 1995; 14:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/7\">",
"      Mart&iacute;nez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004; 23:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/8\">",
"      Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe Staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005; 115:642.",
"     </a>",
"    </li>",
"    <li>",
"     Krogstad P. Osteomyelitis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Philadelphia 2009. p.725.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/10\">",
"      Weber-Chrysochoou C, Corti N, Goetschel P, et al. Pelvic osteomyelitis: a diagnostic challenge in children. J Pediatr Surg 2007; 42:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/11\">",
"      Dich VQ, Nelson JD, Haltalin KC. Osteomyelitis in infants and children. A review of 163 cases. Am J Dis Child 1975; 129:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/12\">",
"      Fernandez M, Carrol CL, Baker CJ. Discitis and vertebral osteomyelitis in children: an 18-year review. Pediatrics 2000; 105:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/13\">",
"      Ham KN, Hurley JV, Ryan GB, Storey E. Localization of particulate carbon in metaphyseal vessels of growing rats. Aust J Exp Biol Med Sci 1965; 43:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/14\">",
"      Anderson CE, Parker J. Invasion and resorption in enchondral ossification. An electron microscopic study. J Bone Joint Surg Am 1966; 48:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/15\">",
"      Emslie KR, Nade S. Pathogenesis and treatment of acute hematogenous osteomyelitis: evaluation of current views with reference to an animal model. Rev Infect Dis 1986; 8:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/16\">",
"      P&ouml;yhi&auml; T, Azouz EM. MR imaging evaluation of subacute and chronic bone abscesses in children. Pediatr Radiol 2000; 30:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/17\">",
"      Ramos OM. Chronic osteomyelitis in children. Pediatr Infect Dis J 2002; 21:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/18\">",
"      Ogden JA. Pediatric osteomyelitis and septic arthritis: the pathology of neonatal disease. Yale J Biol Med 1979; 52:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/19\">",
"      Green WT. Osteomyelitis of infants: A disease different from osteomyelitis of older children. Arch Surg 1936; 32:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/20\">",
"      Trueta J. The three types of acute hematogenous osteomyelitis: A clinical and vascular study. J Bone Joint Surg Br 1959; 41:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/21\">",
"      Perlman MH, Patzakis MJ, Kumar PJ, Holtom P. The incidence of joint involvement with adjacent osteomyelitis in pediatric patients. J Pediatr Orthop 2000; 20:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/22\">",
"      Conventry MB, Ghormley RK, Kernohan JW. Intervertebral disc: Its microscopic anatomy and pathology. J Bone Joint Surg 1945; 27:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/23\">",
"      Cushing AH. Diskitis in children. Clin Infect Dis 1993; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/24\">",
"      Bonhoeffer J, Haeberle B, Schaad UB, Heininger U. Diagnosis of acute haematogenous osteomyelitis and septic arthritis: 20 years experience at the University Children's Hospital Basel. Swiss Med Wkly 2001; 131:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/25\">",
"      Karwowska A, Davies HD, Jadavji T. Epidemiology and outcome of osteomyelitis in the era of sequential intravenous-oral therapy. Pediatr Infect Dis J 1998; 17:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/26\">",
"      Floyed RL, Steele RW. Culture-negative osteomyelitis. Pediatr Infect Dis J 2003; 22:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/27\">",
"      Bocchini CE, Hulten KG, Mason EO Jr, et al. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 2006; 117:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/28\">",
"      Gonzalez BE, Teruya J, Mahoney DH Jr, et al. Venous thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics 2006; 117:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/29\">",
"      McCaskill ML, Mason EO Jr, Kaplan SL, et al. Increase of the USA300 clone among community-acquired methicillin-susceptible Staphylococcus aureus causing invasive infections. Pediatr Infect Dis J 2007; 26:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/30\">",
"      Ritz N, Curtis N. The role of Panton-Valentine leukocidin in Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2012; 31:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/31\">",
"      Ibia EO, Imoisili M, Pikis A. Group A beta-hemolytic streptococcal osteomyelitis in children. Pediatrics 2003; 112:e22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/32\">",
"      Bradley JS, Kaplan SL, Tan TQ, et al. Pediatric pneumococcal bone and joint infections. The Pediatric Multicenter Pneumococcal Surveillance Study Group (PMPSSG). Pediatrics 1998; 102:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/33\">",
"      Yagupsky P, Porsch E, St Geme JW 3rd. Kingella kingae: an emerging pathogen in young children. Pediatrics 2011; 127:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/34\">",
"      Verdier I, Gayet-Ageron A, Ploton C, et al. Contribution of a broad range polymerase chain reaction to the diagnosis of osteoarticular infections caused by Kingella kingae: description of twenty-four recent pediatric diagnoses. Pediatr Infect Dis J 2005; 24:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/35\">",
"      Chometon S, Benito Y, Chaker M, et al. Specific real-time polymerase chain reaction places Kingella kingae as the most common cause of osteoarticular infections in young children. Pediatr Infect Dis J 2007; 26:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/36\">",
"      Kiang KM, Ogunmodede F, Juni BA, et al. Outbreak of osteomyelitis/septic arthritis caused by Kingella kingae among child care center attendees. Pediatrics 2005; 116:e206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/37\">",
"      De Jonghe M, Glaesener G. [Type B Haemophilus influenzae infections. Experience at the Pediatric Hospital of Luxembourg]. Bull Soc Sci Med Grand Duche Luxemb 1995; 132:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/38\">",
"      Sakellaris G, Kampitakis E, Karamitopoulou E, et al. Cat scratch disease simulating a malignant process of the chest wall with coexistent osteomyelitis. Scand J Infect Dis 2003; 35:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/39\">",
"      Mirakhur B, Shah SS, Ratner AJ, et al. Cat scratch disease presenting as orbital abscess and osteomyelitis. J Clin Microbiol 2003; 41:3991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/40\">",
"      Hajjaji N, Hocqueloux L, Kerdraon R, Bret L. Bone infection in cat-scratch disease: a review of the literature. J Infect 2007; 54:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/41\">",
"      Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/42\">",
"      Corrall CJ, Merz WG, Rekedal K, Hughes WT. Aspergillus osteomyelitis in an immunocompetent adolescent: a case report and review of the literature. Pediatrics 1982; 70:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/43\">",
"      Bartkowski SB, Zapala J, Heczko P, Szuta M. Actinomycotic osteomyelitis of the mandible: review of 15 cases. J Craniomaxillofac Surg 1998; 26:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/44\">",
"      Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995; 86:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/45\">",
"      Bennett OM. Salmonella osteomyelitis and the hand-foot syndrome in sickle cell disease. J Pediatr Orthop 1992; 12:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/46\">",
"      Webb DK, Serjeant GR. Haemophilus influenzae osteomyelitis complicating dactylitis in homozygous sickle cell disease. Eur J Pediatr 1990; 149:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/47\">",
"      Chambers JB, Forsythe DA, Bertrand SL, et al. Retrospective review of osteoarticular infections in a pediatric sickle cell age group. J Pediatr Orthop 2000; 20:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/48\">",
"      Burnett MW, Bass JW, Cook BA. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics 1998; 101:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/49\">",
"      HOOK EW, CAMPBELL CG, WEENS HS, COOPER GR. Salmonella osteomyelitis in patients with sickle-cell anemia. N Engl J Med 1957; 257:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/50\">",
"      Syrogiannopoulos GA, McCracken GH Jr, Nelson JD. Osteoarticular infections in children with sickle cell disease. Pediatrics 1986; 78:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17416/abstract/51\">",
"      Sadat-Ali M. The status of acute osteomyelitis in sickle cell disease. A 15-year review. Int Surg 1998; 83:84.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6063 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17416=[""].join("\n");
var outline_f17_0_17416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SITE OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tubular bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nontubular bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Newborns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Older infants and toddlers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vertebral osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bacteria other than staphylococci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fungus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Polymicrobial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pathogens in abnormal hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6063\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6063|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/54/36709\" title=\"diagnostic image 1\">",
"      Brodie abscess radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6063|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/34/35364\" title=\"figure 1\">",
"      Sites of acute osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/47/758\" title=\"figure 2\">",
"      Pathogenesis osteomyelitis children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/14/43237\" title=\"figure 3\">",
"      Developmental pathogenesis osteomyelitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=related_link\">",
"      Back pain in children and adolescents: Overview of causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=related_link\">",
"      Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18506?source=related_link\">",
"      Bone and joint complications in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=related_link\">",
"      Manifestations and treatment of extrapulmonary coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=related_link\">",
"      Pathogenesis of osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=related_link\">",
"      Skeletal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24730?source=related_link\">",
"      Treatment of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_0_17417="Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis";
var content_f17_0_17417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/0/17417/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17417/contributors\">",
"     Andrew G Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17417/contributors\">",
"     Michael Wall, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/0/17417/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17417/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/0/17417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17417/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/0/17417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic intracranial hypertension (IIH) is also commonly called pseudotumor cerebri. It is a disorder defined by clinical criteria that include symptoms and signs isolated to those produced by increased intracranial pressure (eg, headache, papilledema, vision loss), elevated intracranial pressure with normal cerebrospinal fluid composition, and no other cause of intracranial hypertension evident on neuroimaging or other evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While once called benign intracranial hypertension, to distinguish it from secondary intracranial hypertension produced by a neoplastic malignancy, it is not a benign disorder. Many patients suffer from intractable, disabling headaches, and there is a risk of severe, permanent vision loss.",
"   </p>",
"   <p>",
"    This topic will discuss the clinical features and diagnosis of IIH. The epidemiology and pathogenesis, as well as the prognosis and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one case series, the most common symptoms of idiopathic intracranial hypertension (IIH) were [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Headache (92 percent)",
"     </li>",
"     <li>",
"      Transient visual obscurations (72 percent)",
"     </li>",
"     <li>",
"      Intracranial noises (pulsatile tinnitus) (60 percent)",
"     </li>",
"     <li>",
"      Photopsia (54 percent)",
"     </li>",
"     <li>",
"      Retrobulbar pain (44 percent)",
"     </li>",
"     <li>",
"      Diplopia (38 percent)",
"     </li>",
"     <li>",
"      Sustained visual loss (26 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptoms, even as a cluster, are not specific for IIH. In one case-control study, these symptoms were also common in age and gender-matched controls who were recruited from hospital waiting areas; although the prevalence, severity, and frequency were less in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is the most common presenting symptom of IIH. However, the features of headaches in IIH patients are variable and are not specific to IIH. Many, but not all patients note that the pain is of unusual severity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. The headaches are often lateralized and throbbing or pulsatile in character. They may be intermittent or persistent, occur daily or less frequently. Associated nausea and vomiting are not infrequent. Some patients describe headache exacerbation with changes in posture and some may report that relief occurs with nonsteroidal anti-inflammatory medications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rest. Retrobulbar pain and pain with eye movement or globe compression are somewhat more specific features for IIH. In some patients, the pain follows a trigeminal or cervical nerve root distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/4\">",
"     4",
"    </a>",
"    ]. Neck stiffness is also commonly reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, the features of headache are consistent with other primary headache disorders including migraine and tension-type headache [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The often refractory nature of the headache may lead the patient to overuse analgesic medication, suggesting or even causing a superimposed rebound headache, further obscuring the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3624?source=see_link&amp;anchor=H8#H8\">",
"     \"Headache syndromes other than migraine\", section on 'Medication overuse headache'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rare patients present without headache [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Among younger children, headache is a less universal finding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]; in one series, 29 percent of children with IIH did not have headache [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/12\">",
"     12",
"    </a>",
"    ]. In one large case series, men were less likely to complain of headache than women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Visual symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient visual obscurations occur in about two-thirds of patients with papilledema. These last seconds at a time and can be bilateral or unilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/2\">",
"     2",
"    </a>",
"    ]. The frequency is variable, ranging from rare or isolated episodes to those occurring several times a day. Some patients note that these can be precipitated by changes in position (usually standing, but sometimes lying down or bending over), Valsalva, bright light, or eye movement (ie, gaze-evoked) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The occurrence of transient visual obscurations does not appear to correlate with the degree of intracranial pressure elevation or the extent of disc swelling, and is not predictive of future visual loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/3,14\">",
"     3,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Photopsias, brief sparkles or flashes of light, can also occur in patients with IIH and, similar to visual obscurations, can be provoked by positional changes and Valsalva [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subset of individuals with IIH have a more malignant or fulminant course with rapid development of vision loss within a few weeks of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. This is generally apparent at presentation. To limit the severity of permanent vision loss, more aggressive treatment measures are considered at the outset, after the diagnosis is established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intracranial noise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsatile tinnitus is common in IIH and in the setting of headache is somewhat specific for the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/3,8,19\">",
"     3,8,19",
"    </a>",
"    ]. Patients often describe hearing rushing water or wind. This symptom can be persistent or intermittent and is believed to represent vascular pulsations transmitted by cerebrospinal fluid under high pressure to the venous sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diplopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IIH may report intermittent or continuous horizontal diplopia. This is typically due to a unilateral or bilateral sixth cranial nerve palsy from increased intracranial pressure. Rarely, other causes of diplopia can occur in IIH (eg, other cranial neuropathies, decompensated phoria) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Other cranial nerve deficits'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common signs in IIH are",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Papilledema",
"     </li>",
"     <li>",
"      Visual field loss",
"     </li>",
"     <li>",
"      Sixth nerve palsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Papilledema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papilledema is the hallmark sign of IIH (",
"    <a class=\"graphic graphic_picture graphicRef59423 graphicRef72175 \" href=\"UTD.htm?41/32/42502\">",
"     picture 1A-B",
"    </a>",
"    ). Papilledema is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30552?source=see_link\">",
"     \"Overview and differential diagnosis of papilledema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While typically bilateral and symmetric, papilledema may be asymmetric or frankly unilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. In one series, 10 percent of 478 IIH patients had highly asymmetric papilledema with greater visual loss in the eye with higher grade of papilledema [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/22\">",
"     22",
"    </a>",
"    ]. Such patients may also have a relative afferent pupillary defect.",
"   </p>",
"   <p>",
"    Papilledema can be graded in severity. We use the Fris&eacute;n scale for grading papilledema (",
"    <a class=\"graphic graphic_table graphicRef73887 \" href=\"UTD.htm?15/29/15836\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef54781 graphicRef80991 graphicRef59423 graphicRef72175 graphicRef52170 graphicRef60928 \" href=\"UTD.htm?36/17/37146\">",
"     picture 1A-F",
"    </a>",
"    ). Patients with more severe papilledema are at higher risk of permanent visual loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/22\">",
"     22",
"    </a>",
"    ]. We take photographs of both optic discs and grade the severity of papilledema at the initial visit and each follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=see_link&amp;anchor=H4#H4\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment\", section on 'General treatment and follow-up considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other findings on funduscopic examination may include choroidal compression folds across the macula, choroidal neovascularization, and serious retinal elevation around the nerve head [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are some reports of IIH without papilledema [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/7-9,26-29\">",
"     7-9,26-29",
"    </a>",
"    ]. These patients typically present with intractable headaches and are diagnosed with IIH after an elevated opening pressure is documented on lumbar puncture. We consider the absence of papilledema to be a rare occurrence in IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/1\">",
"     1",
"    </a>",
"    ]. Such patients are typically not at risk for vision loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/7,30\">",
"     7,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Visual loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of vision is the major morbidity in IIH and may be present on initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. Vision loss is usually gradual but can be abrupt. Such patients have a more fulminant course and more significant permanent vision loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=see_link&amp;anchor=H3#H3\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment\", section on 'Fulminant IIH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Visual acuity is less than",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    in 10 to 29 percent of patients on presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/2,31-33\">",
"     2,31-33",
"    </a>",
"    ]. However, visual acuity is an insensitive measure of vision loss in IIH. Visual field loss occurs before loss of acuity; confrontation visual fields are abnormal (nasal loss, temporal loss, visual blurring) in up to 32 percent at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/2,33\">",
"     2,33",
"    </a>",
"    ]. Perimetry gives a more accurate and detailed assessment of visual field abnormalities and is an essential feature of the evaluation of a patient with IIH. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Visual field testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The visual field loss is typically peripheral with predominate nerve fiber bundle type defects. Central visual field can be involved late in the course or earlier if there is concomitant macular pathology (serous detachment, macular hemorrhage, or edema), choroidal folds, or choroidal neovascular membrane. In addition to chronic papilledema, other mechanisms, such as a serous retinal detachment, may produce visual loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Abducens palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sixth cranial nerve (abducens) palsy may be unilateral or bilateral in patients with IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/9\">",
"     9",
"    </a>",
"    ]. This reflects a nonlocalizing effect of elevated intracranial pressure on the sixth nerve, which has a long intracranial course before exiting the skull.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other cranial nerve deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other cranial nerve deficits that resolve with IIH treatment are noted in case reports. These may be more common in prepubertal children than in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oculomotor [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/21,30,35,36\">",
"       21,30,35,36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Trochlear nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/30,37\">",
"       30,37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Trigeminal nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/21,35,38\">",
"       21,35,38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Facial nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/5,12,35,39\">",
"       5,12,35,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Auditory nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/19,40,41\">",
"       19,40,41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the headache features of IIH are nonspecific, a funduscopic examination is critical to identify patients with IIH. When papilledema is present, this suggests elevated intracranial pressure, which can have many etiologies in addition to IIH. There are also many etiologies of unilateral or bilateral optic disc swelling, which can have a similar appearance to papilledema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Secondary intracranial hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any entity that increases intracranial pressure may lead to papilledema. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intracranial mass lesions (tumor, abscess)",
"     </li>",
"     <li>",
"      Increased cerebrospinal fluid (CSF) production, eg, choroid plexus papilloma",
"     </li>",
"     <li>",
"      Decreased CSF absorption, eg, arachnoid granulation adhesions after bacterial or other infectious meningitis, subarachnoid hemorrhage",
"     </li>",
"     <li>",
"      Obstructive hydrocephalus",
"     </li>",
"     <li>",
"      Obstruction of venous outflow, eg, venous sinus thrombosis, jugular vein compression, neck surgery",
"     </li>",
"     <li>",
"      Idiopathic intracranial hypertension (pseudotumor cerebri)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Secondary intracranial hypertension due to cerebral venous thrombosis can have a very similar clinical presentation as IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Other unusual causes of obstructed venous outflow include transverse sinus septum causing sinus stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/45\">",
"     45",
"    </a>",
"    ]; osteopetrosis of the jugular foramen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]; depressed skull fracture and stenosis of the superior sagittal sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/51\">",
"     51",
"    </a>",
"    ]. Venous hypertension and secondary increase in intracranial hypertension can also be caused by cerebral arteriovenous malformations, dural arteriovenous malformations, and arteriovenous fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/32,52-61\">",
"     32,52-61",
"    </a>",
"    ]. Some patients thought to have IIH have later been discovered to have one of these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/32,42,62,63\">",
"     32,42,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many causes of an elevated optic nerve head. While the term papilledema is sometimes used to describe the findings in these conditions, it should be reserved for patients who have elevated optic disc heads as a consequence of increased intracranial pressure. The Table lists the causes of optic disc swelling (",
"    <a class=\"graphic graphic_table graphicRef54401 \" href=\"UTD.htm?21/28/21963\">",
"     table 2",
"    </a>",
"    ). These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30552?source=see_link\">",
"     \"Overview and differential diagnosis of papilledema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IIH is diagnosed according to the modified Dandy criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms and signs of increased intracranial pressure (eg, headache, transient visual obscurations, pulse synchronous tinnitus, papilledema, visual loss)",
"     </li>",
"     <li>",
"      No other neurologic abnormalities or impaired level of consciousness",
"     </li>",
"     <li>",
"      Elevated intracranial pressure with normal cerebrospinal fluid (CSF) composition",
"     </li>",
"     <li>",
"      A neuroimaging study that shows no etiology for intracranial hypertension",
"     </li>",
"     <li>",
"      No other cause of intracranial hypertension apparent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It follows that the clinical evaluation of IIH includes a complete history, including documentation of any conditions or medications associated with IIH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=see_link&amp;anchor=H4#H4\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\", section on 'Associated conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A complete ocular exam should document formal visual field examination, dilated fundus examination, and optic nerve photographs. Neuroimaging is required to exclude secondary causes of intracranial hypertension, followed by a lumbar puncture to document opening pressure and exclude other conditions.",
"   </p>",
"   <p>",
"    All patients with bilateral optic disc edema should have a measurement of the systemic blood pressure as optic neuropathy related to malignant hypertension can mimic papilledema and can also produce headache and other symptoms that might be mistaken for IIH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some also suggest that all patients with IIH have a complete blood count to exclude an anemia that may be causative or contributory to the patient's condition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with headache and papilledema, the purpose of neuroimaging is to exclude secondary causes of increased intracranial hypertension. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Secondary intracranial hypertension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) is the preferred test. A CT scan may be necessary for patients with contraindications to MR imaging (eg, pacemakers, metallic clips in head, metallic foreign bodies) and obese or claustrophobic patients. The use of contrast enhancement increases the sensitivity of the study particularly for subtle intracranial masses (eg, gliomatosis cerebri) and meningeal-based pathologies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MRI often shows abnormalities suggestive of IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flattening of the posterior sclera (80 percent)",
"     </li>",
"     <li>",
"      Distension of perioptic subarachnoid space (50 percent)",
"     </li>",
"     <li>",
"      Enhancement (with gadolinium) of the prelaminar optic nerve (45 percent)",
"     </li>",
"     <li>",
"      Empty sella (70 percent)",
"     </li>",
"     <li>",
"      Intraocular protrusion of the prelaminar optic nerve (30 percent)",
"     </li>",
"     <li>",
"      Vertical tortuosity of the orbital optic nerve (40 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are not, individually or in the aggregate, diagnostic of IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/66,70\">",
"     66,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While many cases of cerebral venous thromboses (CVT) are visualized on MRI, MR venography (MRV), particularly with contrast administration, is more sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/62\">",
"     62",
"    </a>",
"    ]. It is our practice to include a postcontrast MRV with MRI when evaluating patients with suspected IIH. If a patient comes to us with a normal MRI without MRV, and there are no other risk factors for CVT (including no oral contraceptive use), and the patient has a typical risk profile for IIH (an obese woman of childbearing age), we may defer MRV unless there is rapid clinical progression or poor response to treatment.",
"   </p>",
"   <p>",
"    There are many reports of cerebral venous abnormalities on MRV in patients with IIH. While the presence of clear venous sinus thrombosis had definite clinical significance, the relationship between apparent venous sinus narrowing or stenosis is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=see_link&amp;anchor=H8#H8\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\", section on 'Intracranial venous hypertension'",
"    </a>",
"    .) Patients with equivocal findings on MRV may require further diagnostic evaluation to exclude CVT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the neuroimaging study reveals no structural etiology for intracranial hypertension, a lumbar puncture (LP) is performed. In addition to measuring the opening pressure, the cerebrospinal fluid (CSF) is analyzed for cell count and differential, glucose, and protein. Appropriate CSF studies for microbial agents, CSF cytology, and antigen testing (eg, CSF VDRL) may be indicated if the CSF content is abnormal or the clinical situation suggests additional testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=see_link\">",
"     \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The upper limit of normal for opening pressure in adults is 200 mmH2O. Some believe that obese patients may have a higher upper limit of normal, with opening pressures that may normally approach 250 mmH2O [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/71\">",
"     71",
"    </a>",
"    ]. However, others have not correlated obesity with elevated intracranial pressure in the absence of IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. We and others consider pressures less than 200 mmH2O to be normal, greater than 250 mmH2O to be abnormal, and 200-250 mmH2O to be equivocal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/1,65,72\">",
"     1,65,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In young children, both higher [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/74,75\">",
"     74,75",
"    </a>",
"    ] and lower [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] upper limits of normal have been proposed. In one case series of 197 pediatric patients without symptoms or other evidence for increased intracranial pressure, the authors determined the upper limit of normal (based upon the 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile) to be 280 mmH2O, and 250 mmH2O in children who were not sedated or obese [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/74\">",
"     74",
"    </a>",
"    ]. In a follow-up study, only 1 of 36 children with IIH had a pressure lower than 280 mmH2O (220 mmH2O), while 16 of 40 control patients had an opening pressure greater than 200 mmH2O (all were less than 280 mmH2O) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/75\">",
"     75",
"    </a>",
"    ]. As with adults, it seems reasonable to consider very elevated levels (&gt;280 mmH2O) to be unequivocally abnormal, while intermediate levels (200 to 280 mmH2O) should be interpreted along with the preponderance of other clinical data that suggests a diagnosis of IIH.",
"   </p>",
"   <p>",
"    For accurate recordings, the patient should be relaxed and lying in the lateral decubitus position with legs extended [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/65\">",
"     65",
"    </a>",
"    ]. Other positions (prone, sitting) can give falsely elevated readings, as can anxiety and pain and the use of sedating medications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/74\">",
"     74",
"    </a>",
"    ]. Misleading low readings can be obtained after multiple LP attempts or in the setting of hyperventilation and treatment with intracranial pressure lowering medications. CSF pressures can vary, and a normal reading in a patient with IIH may reflect an atypically low reading for that patient. Repeating the LP may be required in a patient if suspicion for IIH remains high after one normal CSF reading [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. In rare patients, CSF pressure monitoring may be required to document elevated CSF pressure, but this is exceptional [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Visual field testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual field testing is essential in IIH to assess the severity of optic nerve involvement and monitor response to treatment. Options include Goldmann kinetic perimetry and the computer-assisted static perimetry. While each has advantages and limitations, the latter is generally preferred, as it provides a more reliable measure for follow-up examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common findings on perimetry are [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/25,78-80\">",
"     25,78-80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enlarged blind spot",
"     </li>",
"     <li>",
"      Generalized constriction",
"     </li>",
"     <li>",
"      Inferonasal vision loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less commonly central, paracentral arcuate and altitudinal scotomas may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of visual field loss and acuity loss with IIH is somewhat variable. In one case series, Goldmann perimetry was abnormal in at least one eye in 96 percent of patients on the initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/2\">",
"     2",
"    </a>",
"    ]. Grade 2 loss or higher in at least one eye was present 62 percent. In other reports, visual field loss was noted in 71 to 100 percent of eyes using various forms of perimetry [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/11,32,78,81\">",
"     11,32,78,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confocal scanning tomography is a technique that provides a quantitative measure of papilledema and has been shown to correlate with CSF opening pressure and with visual field sensitivity losses and recovery with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17417/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. While this technique may prove clinically useful, it is not widely available, nor is it clear that it offers significant clinical information over perimetry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/51/38706?source=see_link\">",
"       \"Patient information: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of idiopathic intracranial hypertension (IIH) are believed to result directly from increased intracranial pressure and in most patients include headache and papilledema.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The characteristics of the headache in IIH are variable and nonspecific, but usually include daily occurrence, unusual severity, and a throbbing quality. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Headache'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Papilledema is usually bilateral and symmetric; the severity of papilledema is associated with the risk of permanent visual loss. Grading the severity of papilledema and taking photographs of the optic discs is a useful mechanism for following the patient's course and response to treatment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Papilledema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other common features of IIH that are unusual in other primary headache disorders are transient visual obscurations, pulsatile tinnitus, and diplopia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other common examination features include restricted visual fields and uni- or bilateral abducens palsy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IIH must be distinguished from other causes of increased intracranial pressure and other etiologies of optic nerve head swelling. Cerebral venous thrombosis in particular may have a very similar clinical presentation to IIH. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A neuroimaging study is required in patients suspected as having increased intracranial pressure to exclude other causes of elevated intracranial pressure. Magnetic resonance imaging (MRI) with and without contrast and including postcontrast MR venography is the imaging study of choice. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbar puncture should follow MRI unless a source of elevated intracranial pressure is clearly delineated. An opening pressure greater than 250 mm water taken with the patient lying on his side with legs extended confirms elevated intracranial pressure. Pressures between 200 and 250 mm water are considered equivocal. Cerebrospinal fluid analysis should be normal in IIH. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Lumbar puncture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Visual field testing is an essential part of the evaluation of patients with IIH and provides a means for following the patient and directing treatment (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Visual field testing'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/1\">",
"      Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/2\">",
"      Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 ( Pt 1A):155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/3\">",
"      Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. Neurology 1991; 41:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/4\">",
"      Wall M. The headache profile of idiopathic intracranial hypertension. Cephalalgia 1990; 10:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/5\">",
"      Lessell S. Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). Surv Ophthalmol 1992; 37:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/6\">",
"      Friedman DI, Rausch EA. Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology 2002; 58:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/7\">",
"      Mathew NT, Ravishankar K, Sanin LC. Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Neurology 1996; 46:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/8\">",
"      Wang SJ, Silberstein SD, Patterson S, Young WB. Idiopathic intracranial hypertension without papilledema: a case-control study in a headache center. Neurology 1998; 51:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/9\">",
"      Quattrone A, Bono F, Fera F, Lavano A. Isolated unilateral abducens palsy in idiopathic intracranial hypertension without papilledema. Eur J Neurol 2006; 13:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/10\">",
"      Torun N, Sharpe J. Pseudotumor cerebri mimicking Foster Kennedy syndrome. Neuroophthalmology 1996; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/11\">",
"      Cinciripini GS, Donahue S, Borchert MS. Idiopathic intracranial hypertension in prepubertal pediatric patients: characteristics, treatment, and outcome. Am J Ophthalmol 1999; 127:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/12\">",
"      Lim M, Kurian M, Penn A, et al. Visual failure without headache in idiopathic intracranial hypertension. Arch Dis Child 2005; 90:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/13\">",
"      Bruce BB, Kedar S, Van Stavern GP, et al. Idiopathic intracranial hypertension in men. Neurology 2009; 72:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/14\">",
"      Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/15\">",
"      Thambisetty M, Lavin PJ, Newman NJ, Biousse V. Fulminant idiopathic intracranial hypertension. Neurology 2007; 68:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/16\">",
"      Liu GT, Glaser JS, Schatz NJ. High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri. Am J Ophthalmol 1994; 118:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/17\">",
"      Kidron D, Pomeranz S. Malignant pseudotumor cerebri. Report of two cases. J Neurosurg 1989; 71:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/18\">",
"      Fraser CL, Biousse V, Newman NJ. Minocycline-induced fulminant intracranial hypertension. Arch Neurol 2012; 69:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/19\">",
"      Rudnick E, Sismanis A. Pulsatile tinnitus and spontaneous cerebrospinal fluid rhinorrhea: indicators of benign intracranial hypertension syndrome. Otol Neurotol 2005; 26:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/20\">",
"      Sismanis A, Butts FM, Hughes GB. Objective tinnitus in benign intracranial hypertension: an update. Laryngoscope 1990; 100:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/21\">",
"      Chari C, Rao NS. Benign intracranial hypertension--its unusual manifestations. Headache 1991; 31:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/22\">",
"      Wall M, White WN 2nd. Asymmetric papilledema in idiopathic intracranial hypertension: prospective interocular comparison of sensory visual function. Invest Ophthalmol Vis Sci 1998; 39:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/23\">",
"      Greenfield DS, Wanichwecharungruang B, Liebmann JM, Ritch R. Pseudotumor cerebri appearing with unilateral papilledema after trabeculectomy. Arch Ophthalmol 1997; 115:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/24\">",
"      Saito J, Kami M, Taniguchi F, et al. Unilateral papilledema after bone marrow transplantation. Bone Marrow Transplant 1999; 23:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/25\">",
"      Acheson JF. Idiopathic intracranial hypertension and visual function. Br Med Bull 2006; 79-80:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/26\">",
"      Krishna R, Kosmorsky GS, Wright KW. Pseudotumor cerebri sine papilledema with unilateral sixth nerve palsy. J Neuroophthalmol 1998; 18:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/27\">",
"      Marcelis J, Silberstein SD. Idiopathic intracranial hypertension without papilledema. Arch Neurol 1991; 48:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/28\">",
"      Vieira DS, Masruha MR, Gon&ccedil;alves AL, et al. Idiopathic intracranial hypertension with and without papilloedema in a consecutive series of patients with chronic migraine. Cephalalgia 2008; 28:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/29\">",
"      Beri S, Gosalakkal JA, Hussain N, et al. Idiopathic intracranial hypertension without papilledema. Pediatr Neurol 2010; 42:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/30\">",
"      Soler D, Cox T, Bullock P, et al. Diagnosis and management of benign intracranial hypertension. Arch Dis Child 1998; 78:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/31\">",
"      Rangwala LM, Liu GT. Pediatric idiopathic intracranial hypertension. Surv Ophthalmol 2007; 52:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/32\">",
"      Celebisoy N, Se&ccedil;il Y, Aky&uuml;rekli O. Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey. Acta Neurol Scand 2002; 106:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/33\">",
"      Salman MS, Kirkham FJ, MacGregor DL. Idiopathic \"benign\" intracranial hypertension: case series and review. J Child Neurol 2001; 16:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/34\">",
"      Warman R. Management of pseudotumor cerebri in children. Int Pediatr 2000; 15:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/35\">",
"      Capobianco DJ, Brazis PW, Cheshire WP. Idiopathic intracranial hypertension and seventh nerve palsy. Headache 1997; 37:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/36\">",
"      Tan H. Bilateral oculomotor palsy secondary to pseudotumor cerebri. Pediatr Neurol 2010; 42:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/37\">",
"      Speer C, Pearlman J, Phillips PH, et al. Fourth cranial nerve palsy in pediatric patients with pseudotumor cerebri. Am J Ophthalmol 1999; 127:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/38\">",
"      Arsava EM, Uluc K, Nurlu G, Kansu T. Electrophysiological evidence of trigeminal neuropathy in pseudotumor cerebri. J Neurol 2002; 249:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/39\">",
"      Selky AK, Dobyns WB, Yee RD. Idiopathic intracranial hypertension and facial diplegia. Neurology 1994; 44:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/40\">",
"      Dorman PJ, Campbell MJ, Maw AR. Hearing loss as a false localising sign in raised intracranial pressure. J Neurol Neurosurg Psychiatry 1995; 58:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/41\">",
"      Malomo AO, Idowu OE, Shokunbi MT, et al. Non-operative management of benign intracranial hypertension presenting with complete visual loss and deafness. Pediatr Neurosurg 2006; 42:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/42\">",
"      Biousse V, Ameri A, Bousser MG. Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. Neurology 1999; 53:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/43\">",
"      Leker RR, Steiner I. Features of dural sinus thrombosis simulating pseudotumor cerebri. Eur J Neurol 1999; 6:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/44\">",
"      Sylaja PN, Ahsan Moosa NV, Radhakrishnan K, et al. Differential diagnosis of patients with intracranial sinus venous thrombosis related isolated intracranial hypertension from those with idiopathic intracranial hypertension. J Neurol Sci 2003; 215:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/45\">",
"      Subramaniam RM, Tress BM, King JO, et al. Transverse sinus septum: a new aetiology of idiopathic intracranial hypertension? Australas Radiol 2004; 48:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/46\">",
"      Angeli SI, Sato Y, Gantz BJ. Glomus jugulare tumors masquerading as benign intracranial hypertension. Arch Otolaryngol Head Neck Surg 1994; 120:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/47\">",
"      Jicha GA, Suarez GA. Pseudotumor cerebri reversed by cardiac septal defect repair. Neurology 2003; 60:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/48\">",
"      Kiers L, King JO. Increased intracranial pressure following bilateral neck dissection and radiotherapy. Aust N Z J Surg 1991; 61:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/49\">",
"      Lam BL, Schatz NJ, Glaser JS, Bowen BC. Pseudotumor cerebri from cranial venous obstruction. Ophthalmology 1992; 99:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/50\">",
"      Siatkowski RM, Vilar NF, Sternau L, Coin CG. Blindness from bad bones. Surv Ophthalmol 1999; 43:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/51\">",
"      Fuentes S, Metellus P, Levrier O, et al. Depressed skull fracture overlying the superior sagittal sinus causing benign intracranial hypertension. Description of two cases and review of the literature. Br J Neurosurg 2005; 19:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/52\">",
"      Adelman JU. Headaches and papilledema secondary to dural arteriovenous malformation. Headache 1998; 38:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/53\">",
"      Chimowitz MI, Little JR, Awad IA, et al. Intracranial hypertension associated with unruptured cerebral arteriovenous malformations. Ann Neurol 1990; 27:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/54\">",
"      Cockerell OC, Lai HM, Ross-Russell RW. Pseudotumour cerebri associated with arteriovenous malformations. Postgrad Med J 1993; 69:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/55\">",
"      Cognard C, Casasco A, Toevi M, et al. Dural arteriovenous fistulas as a cause of intracranial hypertension due to impairment of cranial venous outflow. J Neurol Neurosurg Psychiatry 1998; 65:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/56\">",
"      David CA, Peerless SJ. Pseudotumor syndrome resulting from a cerebral arteriovenous malformation: case report. Neurosurgery 1995; 36:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/57\">",
"      Lee, A, Hayman, L, Alpert, J, et al. Occult cerebral vascular causes of pseudotumor cerebri. Neuroophthalmology 1999; 21:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/58\">",
"      Martin TJ, Bell DA, Wilson JA. Papilledema in a man with an \"occult\" dural arteriovenous malformation. J Neuroophthalmol 1998; 18:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/59\">",
"      Rosenfeld JV, Widaa HA, Adams CB. Cerebral arteriovenous malformation causing benign intracranial hypertension--case report. Neurol Med Chir (Tokyo) 1991; 31:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/60\">",
"      Silberstein P, Kottos P, Worner C, et al. Dural arteriovenous fistulae causing pseudotumour cerebri syndrome in an elderly man. J Clin Neurosci 2003; 10:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/61\">",
"      Vorstman EB, Niemann DB, Molyneux AJ, Pike MG. Benign intracranial hypertension associated with arteriovenous malformation. Dev Med Child Neurol 2002; 44:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/62\">",
"      Lin A, Foroozan R, Danesh-Meyer HV, et al. Occurrence of cerebral venous sinus thrombosis in patients with presumed idiopathic intracranial hypertension. Ophthalmology 2006; 113:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/63\">",
"      Tehindrazanarivelo A, Evrard S, Schaison M, et al. Prospective study of cerebral sinus venous thrombosis in patients presenting with benign intracranial hypertension. Cerebrovasc Dis 1992; 2:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/64\">",
"      Biousse V, Rucker JC, Vignal C, et al. Anemia and papilledema. Am J Ophthalmol 2003; 135:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/65\">",
"      Friedman DI. Papilledema and pseudotumor cerebri. Ophthalmol Clin North Am 2001; 14:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/66\">",
"      Brodsky MC, Vaphiades M. Magnetic resonance imaging in pseudotumor cerebri. Ophthalmology 1998; 105:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/67\">",
"      Gibby WA, Cohen MS, Goldberg HI, Sergott RC. Pseudotumor cerebri: CT findings and correlation with vision loss. AJR Am J Roentgenol 1993; 160:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/68\">",
"      Jacobson DM, Karanjia PN, Olson KA, Warner JJ. Computed tomography ventricular size has no predictive value in diagnosing pseudotumor cerebri. Neurology 1990; 40:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/69\">",
"      Manfr&eacute; L, Lagalla R, Mangiameli A, et al. Idiopathic intracranial hypertension: orbital MRI. Neuroradiology 1995; 37:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/70\">",
"      Agid R, Farb RI, Willinsky RA, et al. Idiopathic intracranial hypertension: the validity of cross-sectional neuroimaging signs. Neuroradiology 2006; 48:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/71\">",
"      Whiteley W, Al-Shahi R, Warlow CP, et al. CSF opening pressure: reference interval and the effect of body mass index. Neurology 2006; 67:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/72\">",
"      Corbett JJ, Mehta MP. Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri. Neurology 1983; 33:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/73\">",
"      Bono F, Lupo MR, Serra P, et al. Obesity does not induce abnormal CSF pressure in subjects with normal cerebral MR venography. Neurology 2002; 59:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/74\">",
"      Avery RA, Shah SS, Licht DJ, et al. Reference range for cerebrospinal fluid opening pressure in children. N Engl J Med 2010; 363:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/75\">",
"      Avery RA, Licht DJ, Shah SS, et al. CSF opening pressure in children with optic nerve head edema. Neurology 2011; 76:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/76\">",
"      Spence JD, Amacher AL, Willis NR. Benign intracranial hypertension without papilledema: role of 24-hour cerebrospinal fluid pressure monitoring in diagnosis and management. Neurosurgery 1980; 7:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/77\">",
"      Torbey MT, Geocadin RG, Razumovsky AY, et al. Utility of CSF pressure monitoring to identify idiopathic intracranial hypertension without papilledema in patients with chronic daily headache. Cephalalgia 2004; 24:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/78\">",
"      Wall M, George D. Visual loss in pseudotumor cerebri. Incidence and defects related to visual field strategy. Arch Neurol 1987; 44:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/79\">",
"      Rowe FJ, Sarkies NJ. Assessment of visual function in idiopathic intracranial hypertension: a prospective study. Eye (Lond) 1998; 12 ( Pt 1):111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/80\">",
"      Wall M. Sensory visual testing in idiopathic intracranial hypertension: measures sensitive to change. Neurology 1990; 40:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/81\">",
"      Galvin JA, Van Stavern GP. Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. J Neurol Sci 2004; 223:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/82\">",
"      Salgarello T, Falsini B, Tedesco S, et al. Correlation of optic nerve head tomography with visual field sensitivity in papilledema. Invest Ophthalmol Vis Sci 2001; 42:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/83\">",
"      Trick GL, Vesti E, Tawansy K, et al. Quantitative evaluation of papilledema in pseudotumor cerebri. Invest Ophthalmol Vis Sci 1998; 39:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17417/abstract/84\">",
"      Heckmann JG, Weber M, J&uuml;nemann AG, et al. Laser scanning tomography of the optic nerve vs CSF opening pressure in idiopathic intracranial hypertension. Neurology 2004; 62:1221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5257 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17417=[""].join("\n");
var outline_f17_0_17417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Visual symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intracranial noise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diplopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Papilledema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Visual loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Abducens palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other cranial nerve deficits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Secondary intracranial hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Visual field testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5257\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5257|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/57/36753\" title=\"picture 1A\">",
"      Optic disc Frisen grade 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/15/19697\" title=\"picture 1B\">",
"      Optic disc Frisen grade 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/48/32512\" title=\"picture 1C\">",
"      Normal optic disc 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/49/4882\" title=\"picture 1D\">",
"      Optic disc Frisen grade 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/61/29648\" title=\"picture 1E\">",
"      Optic disc Frisen grade 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/8/22670\" title=\"picture 1F\">",
"      Optic disc Frisen grade 5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5257|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/29/15836\" title=\"table 1\">",
"      Frisen scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/28/21963\" title=\"table 2\">",
"      Differential diagnosis of papilledema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3624?source=related_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=related_link\">",
"      Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30552?source=related_link\">",
"      Overview and differential diagnosis of papilledema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/51/38706?source=related_link\">",
"      Patient information: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_0_17418="Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations";
var content_f17_0_17418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/0/17418/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17418/contributors\">",
"     Claudine Isaacs, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17418/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17418/contributors\">",
"     Beth N Peshkin, MS, CGC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/0/17418/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17418/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/0/17418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/0/17418/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/0/17418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a family history of breast",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ovarian cancer is common in women diagnosed with breast or ovarian cancer, less than 10 percent of all breast cancers and less than 15 percent of ovarian cancers are associated with germline (inherited) genetic mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The majority of hereditary breast and ovarian cancers are associated with mutations in two genes, breast cancer type 1 and 2 susceptibility genes (BRCA1 and BRCA2). Less commonly, breast cancer is due to other hereditary cancer syndromes, such as Li-Fraumeni and Cowden syndromes, which are related to mutations in the TP53 and PTEN genes, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary breast and ovarian cancer (HBOC) syndrome (ie, due to germline mutations in the BRCA1 and BRCA2 genes) is characterized by an autosomal dominant pattern of inheritance, markedly increased susceptibility to breast and ovarian cancer, with an especially early onset of breast cancer, and an increased incidence of tumors of other organs, such as the fallopian tubes, prostate, male breast, and pancreas.",
"   </p>",
"   <p>",
"    The management of patients with hereditary breast and ovarian cancer syndrome is reviewed here. Selection of appropriate candidates for genetic testing, the characteristics of hereditary breast and ovarian cancer syndromes and their associated cancer risks, and the genetic counseling process are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5064?source=see_link\">",
"       \"Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779410859\">",
"    <span class=\"h1\">",
"     CANCER RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cancer risks are variable in patients with hereditary breast and ovarian cancer (HBOC) syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with HBOC syndrome have markedly elevated risks of breast cancer and ovarian cancer, with a lifetime risk of breast cancer of 50 to 85 percent and a 15 to 40 percent chance of developing ovarian cancer.",
"      <sup>",
"       ",
"      </sup>",
"      There is also an increased risk of a second breast cancer diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men with HBOC syndrome have increased risk of breast cancer and prostate cancer. There is an undefined increased lifetime risk of breast cancer and prostate cancer in men with a BRCA1 gene mutation. In men with a BRCA2 gene mutation, the lifetime risk of breast cancer appears to be under 10 percent and the lifetime risk of prostate cancer is elevated five to seven fold. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link&amp;anchor=H7#H7\">",
"       \"Breast cancer in men\", section on 'Inherited conditions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=see_link&amp;anchor=H8#H8\">",
"       \"Risk factors for prostate cancer\", section on 'BRCA2 and BRCA1'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both men and women with HBOC syndrome have other cancer risks, such as increased risk of pancreatic cancer, especially with mutations in the BRCA2 gene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184686209\">",
"    <span class=\"h2\">",
"     Risks to relatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children of a parent with a BRCA1 or BRCA2 mutation have a 50 percent risk of having inherited the mutation. It is important that adult relatives are informed about this risk and the associated cancer risks, and should be made aware of the options for genetic counseling, testing, and management, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H166733267\">",
"    <span class=\"h1\">",
"     CANCER SCREENING AND PREVENTION GUIDELINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H166733260\">",
"    <span class=\"h2\">",
"     Recommendations of expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening and prevention guidelines from expert groups are based upon nonrandomized trials and observational data. The recommendations included below are derived from a number of studies and are in keeping with the recommendations from National Comprehensive Cancer Network (NCCN). These guidelines based on expert consensus (lower level evidence), are regularly updated, and provide the most comprehensive guidelines currently available. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779411428\">",
"    <span class=\"h1\">",
"     CANCER SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hereditary breast and ovarian cancer (HBOC) syndrome are counseled to initiate screening considerably earlier than average-risk patients due to the early age of diagnosis of several cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/2\">",
"     2",
"    </a>",
"    ]. While breast and ovarian (including fallopian tube and peritoneal) cancers present the greatest risk, individuals with HBOC syndrome may have elevated risks for other cancers, including prostate cancer and pancreatic cancer, as described above.",
"   </p>",
"   <p>",
"    Patients with HBOC syndrome should be educated regarding signs and symptoms of breast and ovarian cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15841789\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following screening strategy is recommended by expert groups for women with HBOC syndrome who have not undergone risk-reducing surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monthly breast self-examination beginning at age 18",
"     </li>",
"     <li>",
"      Clinical breast examination two to four times annually beginning at age 25",
"     </li>",
"     <li>",
"      Annual mammography and breast magnetic resonance imaging (MRI) screening (commonly alternated every six months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/8\">",
"       8",
"      </a>",
"      ]) beginning at age 25 or individualized based on the earliest age of onset in the family &nbsp;",
"     </li>",
"     <li>",
"      Twice yearly ovarian cancer screening with transvaginal ultrasound and serum CA-125 levels (preferably drawn on day 1 to 10 of menstrual cycle for premenopausal women) beginning at age 35, or 5 to 10 years earlier than the earliest age of first diagnosis of ovarian cancer in the family.",
"      <br/>",
"      <br/>",
"      However, the lack of efficacy of ovarian cancer screening has prompted many clinicians to recommend risk-reducing bilateral salpingo-oophorectomy at the completion of childbearing rather than intensified screening for ovarian cancer. Specific issues surrounding screening for ovarian cancer in high-risk populations are discussed in detail elsewhere; risk-reducing salpingo-oophorectomy is also discussed below. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H3#H3\">",
"       \"Screening for ovarian cancer\", section on 'Risk factors'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H4\">",
"       'Salpingo-oophorectomy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15841796\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following screening strategy is recommended for men (with BRCA1 and BRCA2 mutations) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Monthly breast self-examination",
"     </li>",
"     <li>",
"      Clinical breast examination semiannually",
"     </li>",
"     <li>",
"      Baseline mammogram with annual mammogram if baseline study shows gynecomastia or",
"      <span class=\"nowrap\">",
"       parenchymal/glandular",
"      </span>",
"      breast density",
"     </li>",
"     <li>",
"      Appropriate prostate cancer screening",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional cancer screening may be indicated for other cancers associated with HBOC syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H14#H14\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Other cancers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15841803\">",
"    <span class=\"h2\">",
"     Breast cancer screening in women",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1486483\">",
"    <span class=\"h3\">",
"     Mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitivity of mammography for detecting breast cancer in mutation carriers appears to be lower than in other high-risk women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/5,9-11\">",
"     5,9-11",
"    </a>",
"    ]. The lower sensitivity of mammography in women with BRCA mutations may be due to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher breast density [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Differences in morphologic features (eg, less spiculation due to lack of tumor-surrounding fibrosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many of the histopathologic findings seen in the breasts of women undergoing prophylactic mastectomy because of a strong family history of breast cancer (eg, atypical lobular or ductal hyperplasia, lobular carcinoma in situ) are not detectable mammographically [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The frequent development of interval malignancies. In one analysis of women with deleterious BRCA mutations, among 165 women with breast tissue who opted for breast cancer screening, 12 were diagnosed with breast cancer over a two-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/5\">",
"       5",
"      </a>",
"      ]. One-half of these were interval cancers not detected by annual mammography; most were detected by breast self examination.",
"      <br/>",
"      <br/>",
"      Because of the frequent development of interval malignancies, more frequent mammography (eg, every six months) is sometimes considered [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/5,14,15\">",
"       5,14,15",
"      </a>",
"      ]. However, there are no known studies that compare semiannual versus annual screening and thus no data to develop evidence-based recommendations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As will be discussed below, breast cancer detection rates are clearly increased in high risk women undergoing breast MRI as a component of breast cancer surveillance; furthermore, the addition of breast MRI to the surveillance strategy increases the number of patients diagnosed at an earlier stage of disease. Despite this, most guidelines recommend conventional annual mammography in addition to breast MRI for women with an inherited predisposition to breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/5-7,17\">",
"     5-7,17",
"    </a>",
"    ]. While some studies suggest no difference in cancer detection rates from the addition of mammography to MRI as compared to breast MRI alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/18\">",
"     18",
"    </a>",
"    ], others report greater sensitivity for mammography in this setting, particularly for ductal carcinoma in situ (DCIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and meta-analysis concluded that combined use of mammography and MRI is associated with higher sensitivity for detection of breast cancer than MRI alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1486490\">",
"     'Breast MRI'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link&amp;anchor=H100033227#H100033227\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\", section on 'Mammography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings from the GENE-RAD-RISK retrospective cohort study suggest that any radiation exposure before the age of 30 was associated with an increased risk of breast cancer among carriers of a BRCA mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/22\">",
"     22",
"    </a>",
"    ]. The authors concluded that the study supported use of non-ionizing radiation imaging (such as MRI) in young women with",
"    <span class=\"nowrap\">",
"     BRCA1/BRCA2",
"    </span>",
"    mutations. Further data are needed, however, to determine whether such an approach is optimal. We advise that mutation carriers begin annual mammography (as well as MRI, each alternating every six months, see below) at age 25, as in the NCCN guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/6\">",
"     6",
"    </a>",
"    ]. This recommendation may be modified based upon individual factors (eg, breast density). It remains unclear whether the age at initiation of screening should be altered based on a pattern of late-onset cancers within the family, or patient concerns about the risks associated with radiation exposure, or whether one could safely omit mammography in younger age women and screen only with MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link&amp;anchor=H32#H32\">",
"     \"Screening for breast cancer\", section on 'Radiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1486490\">",
"    <span class=\"h3\">",
"     Breast MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of breast MRI to the breast cancer surveillance strategy in high-risk women, such as those with HBOC, increases breast cancer detection rates, increases the number of patients diagnosed at an earlier stage of disease, and is cost-effective (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82565 \" href=\"UTD.htm?28/27/29104\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/20,23-26\">",
"     20,23-26",
"    </a>",
"    ]. Therefore, it is recommended in guidelines from expert groups [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. However, the mortality impact of including breast MRI in the surveillance strategy is not clear. Breast cancer detection rates are clearly increased when high-risk women undergo breast MRI as a component of breast cancer surveillance; furthermore, the addition of breast MRI to the surveillance strategy increases the number of patients diagnosed at an earlier stage of disease .",
"   </p>",
"   <p>",
"    MRI has been found to be more sensitive but less specific than mammography for the detection of invasive cancers in high-risk women in both retrospective [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/10,27-29\">",
"     10,27-29",
"    </a>",
"    ] and prospective [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/20,30-33\">",
"     20,30-33",
"    </a>",
"    ] studies. A systematic review of 11 studies compared test performance of screening MRI to mammography in high-risk women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/21\">",
"     21",
"    </a>",
"    ]. The mean or median age of women in the studies ranged from 40 to 47 years. The women were at very high risk of breast cancer, with a prevalence of 2 percent (about 13 times the overall breast cancer prevalence of approximately 0.15 percent in women of similar age). The following results were found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitivity of MRI was significantly better than that of mammography: 0.77 (95% CI 0.70-0.84) versus 0.39 (CI 0.37-0.41).",
"     </li>",
"     <li>",
"      Specificity of MRI was worse than that of mammography: 0.86 (CI 0.81-0.92) versus 0.95 (CI 0.93-0.97).",
"     </li>",
"     <li>",
"      Sensitivity of MRI and mammography together was 0.94 (CI 0.90-0.97) and specificity was 0.77 (CI 0.75-0.80).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of any surveillance strategy (including MRI) on breast cancer mortality has not been established. The only prospective study that addressed long-term survival was the Dutch MRI Screening Study, in which women with high-risk for breast cancer (&gt;15 percent cumulative lifetime risk) were screened with annual mammography and MRI (and biannual clinical breast examination); those who developed breast cancer were followed for a median of five years after diagnosis. The cumulative distant-metastasis free and overall survival at six years in the 42",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    mutation carriers with invasive cancer was 83.9 percent (95% CI, 64.1-93.3) and 92.7 percent (95% CI, 79.0-97.6), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/20\">",
"     20",
"    </a>",
"    ]. This is in contrast to a median overall survival of 74.5 percent (range 50 to 95 percent) for an historical cohort of 1081",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    mutation carriers. While these data are promising, they do not prove a mortality benefit from breast MRI.",
"   </p>",
"   <p>",
"    BRCA1-associated breast cancers present differently from BRCA2 and other familial cases of breast cancer. This was shown in a later report of the entire cohort from this study (n=2157 women, ages 25 to 75) that further analyzed the effects of MRI and mammography screening according to subgroups of breast cancer risk: lifetime risks of 50 to 80 percent (BRCA1 mutations, BRCA2 mutations, and",
"    <span class=\"nowrap\">",
"     PTEN/TP53",
"    </span>",
"    mutations); 30 to 50 percent (based on family history); and 15 to 30 percent (based upon family history) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall sensitivity was 71 percent for MRI, 41 percent for mammography and 21 percent for CBE. MRI was more sensitive than mammography for invasive cancers (77 versus 36 percent); mammography showed a trend toward greater sensitivity than MRI for DCIS (69 versus 39 percent) although this difference was not statistically significant.",
"     </li>",
"     <li>",
"      Overall specificity was 90 percent for MRI, 95 percent for mammography and 98 percent for CBE.",
"     </li>",
"     <li>",
"      The positive predictive value of mammography was higher among BRCA2 mutation carriers than among BRCA1 mutation carriers. Positive predictive value for MRI varied, but not significantly, by subgroup.",
"     </li>",
"     <li>",
"      As expected, breast cancer detection rates were much higher among mutation carriers than in women at increased risk because of family history (26.3 and 39.2 versus 5.6 and 6.9 per 1000 woman-years at risk). Breast cancer was diagnosed at younger ages in mutation carriers; 58 percent of BRCA1 and 50 percent of BRCA2 mutation carriers were diagnosed before age 40.",
"     </li>",
"     <li>",
"      Breast cancers diagnosed among BRCA1 mutation carriers were significantly more likely to be larger, have higher histologic grade and have negative estrogen and progesterone receptor status. DCIS accounted for only 6.5 percent of breast cancers in BRCA1 carriers compared to 18.8 percent in BRCA2 carriers, 14.8 percent in women with 30 to 50 percent risk, and 31.3 percent in women with 15 to 30 percent risk, although the differences were not significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of the Dutch MRI study support MRI screening for women at highest risk for breast cancer, although numbers are small and conclusions are subject to multiple biases (patient selection, lead time bias, treatment differences) affecting observational studies in the absence of randomized trials. The study results also suggest that BRCA1 mutation carriers are at greater risk of developing cancers with poorer prognosis than BRCA2 mutation carriers and other women at increased risk. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1487041\">",
"    <span class=\"h2\">",
"     Ovarian cancer screening in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic screening of women with HBOC who have not undergone prophylactic oophorectomy, using a combination of the serum tumor marker CA 125 and transvaginal ultrasound, is recommended in guidelines from expert groups. While there are no high quality data on which to base recommendations regarding timing of screening, some have suggested initiation at age 35 years or five to ten years earlier than the earliest age of first diagnosis of ovarian cancer in the family. The evidence and recommendations for ovarian cancer screening in women with HBOC are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H23#H23\">",
"     \"Screening for ovarian cancer\", section on 'High-risk family history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK-REDUCING SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HBOC syndrome, prophylactic mastectomy reduces the risk of developing breast cancer, while risk-reducing salpingo-oophorectomy reduces the risk of both ovarian cancer and breast cancer (the latter when performed premenopausally).",
"   </p>",
"   <p>",
"    While prophylactic surgery is effective in cancer risk-reduction, patients should be counselled preoperatively about the morbidity of such procedures, their impact on libido and sexual functioning, body image, and bone and cardiac health, and issues regarding surgical menopause and hormone therapy. They should also be aware that risk-reducing surgery is not 100 percent effective, given the remote possibility that not all at-risk tissue is removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both retrospective and prospective studies, risk-reducing or prophylactic bilateral mastectomy has been shown to decrease the incidence of breast cancer by as much as 90 percent or more in patients at risk of hereditary breast cancer and in BRCA 1 and BRCA 2 mutation carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/14,34-39\">",
"     14,34-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one large prospective cohort study of women with BRCA1 or BRCA2 mutations, there were no breast cancer diagnoses during three years of follow-up among women who chose to undergo risk-reducing mastectomy (247 women) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/39\">",
"       39",
"      </a>",
"      ]. In contrast, 7 percent of 1372 women without risk-reducing mastectomy were diagnosed with breast cancer.",
"     </li>",
"     <li>",
"      In a retrospective study with longer follow-up (median 13.4 years), the calculated risk reduction in BRCA1 and BRCA2 mutation carriers after bilateral prophylactic mastectomy (n = 26 women) was 89.5 to 100 percent (95% CI 41.4-100).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A bilateral total mastectomy is often recommended for prophylaxis because subcutaneous mastectomy leaves behind more glandular tissue that remains at risk for future cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/34,40\">",
"     34,40",
"    </a>",
"    ]. However, skin-sparing mastectomy with or without preservation of the nipple-areolar complex provides superior cosmetic results and while data are limited, appears to have no increased risk of local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Most women are candidates for immediate breast reconstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link&amp;anchor=H7005314#H7005314\">",
"     \"Mastectomy\", section on 'Skin-sparing mastectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who develop BRCA-linked ovarian cancer, the predominant cause of mortality at five years is ovarian cancer. Therefore, we suggest that breast cancer screening and risk reduction surgical decisions be made in the context of the ovarian cancer. In a retrospective review of 164 patients with BRCA-linked ovarian cancer, metachronous breast cancer occurred in 18 women (median time to diagnosis 108 months, range 13 to 241), with no deaths reported from breast cancer with a median 5.8 year follow up [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/43\">",
"     43",
"    </a>",
"    ]. The 5-year and 10-year breast-cancer-free survival rates for BRCA carriers was 97 and 91 percent, respectively, while the 5-year and 10-year overall survival rates were 85 percent and 68 percent, respectively. At 10 years of follow up for BRCA-ovarian cancer survivors, the risk of developing breast cancer is less than 10 percent.",
"   </p>",
"   <p>",
"    Contralateral mastectomy in BRCA1 and BRCA2 mutation carriers who have been diagnosed with breast cancer are discussed separately. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment and prognosis of women who develop breast cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Salpingo-oophorectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral risk-reducing salpingo-oophorectomy is recommended for BRCA1 and BRCA2 mutation carriers by age 35 to 40 or when childbearing is completed, or individualized based on age of onset of ovarian cancer in the family [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/5,6,44-47\">",
"     5,6,44-47",
"    </a>",
"    ]. Bilateral salpingo-oophorectomy decreases the risk of both breast cancer and ovarian cancer in BRCA1 and BRCA2 mutation carriers; however, estimates for risk and mortality reduction differ according to baseline cancer risks among BRCA1 and BRCA2 mutation carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/39,44,45\">",
"     39,44,45",
"    </a>",
"    ]. Risk-reducing salpingo-oophorectomy has also been associated with reduced all-cause, breast cancer-specific, and ovarian cancer-specific mortality. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment and prognosis of women who develop breast cancer'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHEMOPREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemopreventive strategies to reduce the risk of breast cancer have focused exclusively on prevention in high-risk women and involve the use of selective estrogen receptor modulators (SERMs) and aromatase inhibitors for breast cancer prevention, while oral contraceptives have been used for chemoprevention of hereditary ovarian cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Breast cancer chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoprevention using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for five years reduces the incidence of breast cancer by approximately 50 percent in women with a moderately increased risk for breast cancer (defined as women over the age of 60 or over age 35 who have a history of lobular carcinoma in situ and those with a five-year estimated risk for breast cancer of at least 1.66 percent as determined by the Gail model, but who do not have HBOC syndrome), a benefit that continues for 5 to 10 years after drug discontinuation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    is slightly less effective than tamoxifen in reducing breast cancer risk, but is associated with fewer serious side effects. Neither drug has shown a reduction in breast cancer mortality or all-cause mortality. In addition, these benefits only appear to pertain to a reduction in hormone-sensitive breast cancer. Most recently, benefit has also been shown for primary prevention with the aromatase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data addressing the preventive benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    or an aromatase inhibitor in patients with BRCA mutations. Only limited data are available regarding the preventive benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in BRCA1 and BRCA2 mutation carriers. Evidence for the benefit of tamoxifen in women who have never had a diagnosis of breast cancer comes from a subset analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention trial (P-1 trial). Tamoxifen reduced breast cancer risk by 62 percent in BRCA2 carriers (RR 0.38, 95% CI 0.06 to 1.56), but not in BRCA1 carriers (RR 1.67, 95% CI 0.32 to 10.07) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/48\">",
"     48",
"    </a>",
"    ]. However this analysis is limited by the small number of mutation carriers (of the 288 women in the study who developed breast cancer, only 8 had BRCA1 mutations and 11 had BRCA2 mutations) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/49\">",
"     49",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    A differential effect of tamoxifen in BRCA2 as compared to BRCA1 mutation carriers may be attributed to estrogen receptor (ER) status of BRCA1- and BRCA2-associated tumors. Tamoxifen might be expected to have an impact only against ER-positive tumors, and BRCA2-associated tumors have a greater likelihood than BRCA1-associated tumors of being ER-positive. However, in other settings, tamoxifen has shown benefit for both BRCA1- and BRCA2-associated tumors, irrespective of ER-status [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/50-52\">",
"     50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who do not opt for risk-reducing surgery may consider surveillance and prevention with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , though this is a less effective alternative to prophylactic mastectomy. As discussed below, tamoxifen has been shown to decrease the risk of contralateral breast cancer in patients with BRCA-associated breast cancer. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment and prognosis of women who develop breast cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Oral contraceptives for prevention of ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptive use in BRCA1 and BRCA2 mutation carriers appears to decrease the risk of ovarian cancer.",
"   </p>",
"   <p>",
"    A meta-analysis of 18 studies, which were either case-control or retrospective cohort studies, of oral contraceptive use in BRCA1 and BRCA2 mutation carriers included 2855 breast cancer cases and 1503 ovarian cancer cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/53\">",
"     53",
"    </a>",
"    ]. Use of oral contraceptives in BRCA1 and BRCA2 mutation carriers was associated with a significantly reduced risk of ovarian cancer [summary relative risk (SRR),&nbsp;0.50, 95% CI 0.33&ndash;0.75]. For each additional 10 years of oral contraceptive use, there was a significantly reduced ovarian cancer risk (SRR 0.64, 95% CI 0.53&ndash;0.78).",
"   </p>",
"   <p>",
"    There is concern that oral contraceptives may increase the risk of breast cancer in mutation carriers. In the meta-analysis described above, there was no evidence of a significantly increased breast cancer risk in oral contraceptive users overall, for recent formulation of oral contraceptives, and in the first 10 years after cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/53\">",
"     53",
"    </a>",
"    ]. Specifically,",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, for BRCA1 and BRCA2 mutation carriers, breast cancer risk was not significantly increased by oral contraceptive use (SRR&nbsp;1.13, 95% CI 0.88&ndash;1.45).",
"     </li>",
"     <li>",
"      Compared to never users,",
"      <span class=\"nowrap\">",
"       BRCA1/2",
"      </span>",
"      carriers who stopped oral contraceptives at least 10 years before diagnosis had a significantly increased risk of breast cancer (SRR&nbsp;1.46, 95% CI 1.07&ndash;2.07), but no significant association was observed for women who stopped oral contraceptive use within 10 years of breast cancer diagnosis.",
"     </li>",
"     <li>",
"      Oral contraceptive formulations used before 1975 were associated with a significantly increased risk of breast cancer (SRR 1.47, 95% CI 1.06-2.04), but no evidence of a significant association was found with use of more recent formulations (SRR 1.17, 95% CI 0.74-1.86).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of oral contraceptives in BRCA1 and BRCA2 mutation carriers remains a controversial issue. Mutation carriers who have used oral contraceptives are still recommended to undergo risk-reducing salpingo-oophorectomy when childbearing is completed. Thus, each woman must carefully weigh the reasons for oral contraceptive use and their potential pros and cons with her physician. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H470979705\">",
"    <span class=\"h2\">",
"     Options for men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who harbor a BRCA mutation are at an increased risk for multiple cancers, including breast and prostate cancers, compared to men who do not [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/54\">",
"     54",
"    </a>",
"    ]. However, the overall incidence of breast cancer in men is low and it is not likely that men with a BRCA mutation would have a high enough risk to warrant anything other than cancer surveillance. The main risk for men who harbor a BRCA mutation appears to be for prostate cancer, but there is no evidence to support the use of chemoprevention to reduce this risk. Therefore, the primary recommendation for men with a BRCA mutation is for cancer surveillance, not chemoprevention. (See",
"    <a class=\"local\" href=\"#H15841796\">",
"     'Men'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link\">",
"     \"Chemoprevention strategies in prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL DECISION MAKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical decisions about which strategies to pursue for cancer risk-reduction (ie, surveillance, risk-reducing surgery,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemoprevention) are difficult dilemmas that may involve a trade-off between life expectancy and quality of life. Several tools (decision aids or models) are available to help with decision making [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/25,26,55-57\">",
"     25,26,55-57",
"    </a>",
"    ]. Most use decision analysis and the concept of time tradeoffs, ie, years of life saved by one strategy as compared to another. As an example;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calculations from one model suggested that an average 30 year old woman with a BRCA1 or BRCA2 mutation would gain from 3 to 5 years of life expectancy from prophylactic mastectomy and from 0.3 to 2 years of life expectancy from risk-reducing oophorectomy, depending on her cumulative risk of cancer. In contrast, gains in life expectancy declined with age at the time of risk-reducing surgery and were minimal for 60-year-old women [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calculations from a different model that compared risk-reducing surgery to surveillance suggested that prophylactic mastectomy at age 25 plus risk-reducing oophorectomy at age 40 years maximized survival probability. However, substituting mammography plus magnetic resonance imaging screening for prophylactic mastectomy seemed to offer comparable survival [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weighing the pros and cons of alternative strategies with a clinical genetics counselor is often easier for patients to conceptualize than the concept of time tradeoffs, and takes individual patient preferences into account.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779411749\">",
"    <span class=\"h1\">",
"     REPRODUCTIVE COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in breast cancer genes (BRCA1 and BRCA2) are inherited in an autosomal dominant pattern, meaning that there is a 50 percent chance that children of",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    carriers will have inherited the cancer-predisposition mutation. Reproductive counseling of BRCA1 and BRCA2 mutation carriers includes education about prenatal diagnosis and assisted reproduction. One option is preimplantation genetic diagnosis, which is used to analyze embryos (obtained by in vitro fertilization) genetically before their transfer into the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/2,58\">",
"     2,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, patients with a BRCA2 mutation who plan to have children with a partner who is also at increased risk of carrying a BRCA2 mutation (eg, owing to family cancer history or to the increased background frequency in individuals of Ashkenazi Jewish descent) are at risk for a rare, recessive syndrome which is characterized by the co-occurrence of brain tumors, Fanconi anemia, and breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/59\">",
"     59",
"    </a>",
"    ]. This syndrome occurs in individuals who have two copies of a BRCA2 mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS OF WOMEN WHO DEVELOP BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women from high-risk families who are diagnosed with breast cancer may wish to undergo",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    testing prior to making treatment decisions, especially definitive surgical decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/60\">",
"     60",
"    </a>",
"    ]. As BRCA1 and BRCA2 mutation carriers have an increased risk of ipsilateral and contralateral breast cancer, women who test positive may choose to undergo bilateral mastectomy, even if they are candidates for breast conservation therapy (BCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BCT appears to be as effective a local treatment option in mutation carriers as in women with sporadic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. &nbsp;There is no evidence to suggest that patients with BRCA-related breast cancers are more radiosensitive or susceptible radiation-associated complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H27#H27\">",
"     \"Breast conserving therapy\", section on 'Inherited susceptibility'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link&amp;anchor=H32573033#H32573033\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Radiation therapy in BRCA mutation carriers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, over the long-term, mutation carriers appear to have higher risks of a new primary in their ipsilateral breast as well as an increased risk of contralateral breast cancer (five-year contralateral breast cancer rates of 10 to 20 percent versus 1 to 3 percent in those with sporadic breast cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/61\">",
"     61",
"    </a>",
"    ]. The risk of contralateral breast cancer is dependent on age at diagnosis of the initial breast cancer, with higher absolute long-term risks noted in those initially diagnosed at a younger age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approaches for minimizing this risk include ipsilateral mastectomy and contralateral prophylactic mastectomy, prevention with a selective estrogen receptor modulator (SERM), and prophylactic bilateral oophorectomy in premenopausal patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contralateral prophylactic mastectomy is an effective and popular option for reducing the risk of contralateral breast cancer recurrence, and evidence suggests that it may improve disease-free and overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/61,67-71\">",
"       61,67-71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      reduces the risk of contralateral breast cancers in patients with breast cancer and either BRCA1 or BRCA2 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/50,52,72,73\">",
"       50,52,72,73",
"      </a>",
"      ]. As an example, the benefit of tamoxifen in BRCA mutation carriers was evaluated in a case control study of 1036 women BRCA mutation carriers with breast cancer, 285 of whom developed a second (bilateral) breast cancer and 751 who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/52\">",
"       52",
"      </a>",
"      ]. The history of tamoxifen use for treating the first breast cancer was compared between bilateral and unilateral cases. The odds ratio [OR] for contralateral breast cancer associated with tamoxifen use was 0.47 (95% CI 0.30-0.74) overall, and the effect was similar for carriers of BRCA1 mutations (OR 0.50, 95% CI 0.30-0.85) and BRCA2 mutations (OR 0.42, 0.17-1.02).",
"      <br/>",
"      <br/>",
"      The main benefit of tamoxifen is in reducing hormone receptor-positive breast cancer. Whether tamoxifen is effective in reducing recurrence in",
"      <span class=\"nowrap\">",
"       BRCA1/2",
"      </span>",
"      carriers with hormone receptor-negative breast cancers is unclear. Furthermore, its additive value in those carriers undergoing risk-reducing salpingo-oophorectomy is not well established [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/74\">",
"       74",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link&amp;anchor=H31421388#H31421388\">",
"       \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Tamoxifen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although bilateral salpingo-oophorectomy decreases the risk of breast cancer (as well as ovarian cancer) in BRCA1 and BRCA2 mutation carriers with and without a prior history of breast cancer, it is not clear that oophorectomy reduces the risk of breast cancer mortality in BRCA1 and BRCA2 mutation carriers with a diagnosis of breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/39,72,73\">",
"       39,72,73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For BRCA1 and BRCA2 mutation carriers with breast cancer who do not opt for contralateral mastectomy, surveillance with clinical breast examination, mammography, and MRI are recommended, as outlined above. (See",
"    <a class=\"local\" href=\"#H779411428\">",
"     'Cancer surveillance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    BRCA-associated breast cancers occur in younger women than sporadic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/19,75\">",
"     19,75",
"    </a>",
"    ]. Compared with BRCA2 and sporadic breast cancer, BRCA1-associated breast cancers are often associated with histopathologic features suggestive of a poor prognosis; they are often poorly differentiated, high grade with high proliferative rate, and with absent expression of estrogen and progesterone receptors, as well as human epidermal growth factor receptor 2 (HER2) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/19,75-81\">",
"     19,75-81",
"    </a>",
"    ]. However, it is not clear that the prognosis of BRCA-associated breast cancers is worse when adjusted for these adverse factors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/78,80-87\">",
"     78,80-87",
"    </a>",
"    ]. In addition, there is limited data regarding the effect of subsequent pregnancy or lactation on BRCA-associated breast cancer prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With regard to decisions about adjuvant chemotherapy, current data regarding the impact of",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    status on breast cancer related prognosis are inconclusive, and thus mutation status generally does not factor into the decision making process regarding the type of systemic therapy. However, there is accumulating evidence of altered sensitivity of systemic agents in BRCA-related breast cancer, especially the increased sensitivity of platinums and poly ADP-ribose polymerase (PARP) inhibitors, and decreased sensitivity of taxanes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/89\">",
"     89",
"    </a>",
"    ]. For BRCA1 and BRCA2 carriers, there is some evidence that the use of chemotherapy, even for small tumors, may significantly improve outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/0/17418/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=see_link&amp;anchor=H158129670#H158129670\">",
"     \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\", section on 'PARP inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=see_link\">",
"       \"Patient information: Genetic testing for breast and ovarian cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"       \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=see_link\">",
"       \"Patient information: Medications for the prevention of breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hereditary breast and ovarian cancers (HBOC) syndrome have inherited mutations in breast cancer type 1 and 2 susceptibility genes (BRCA1 and BRCA2) and markedly elevated risks of breast cancer and ovarian cancer. Men with HBOC syndrome have increased risk for breast and prostate cancer, while both men and women with HBOC syndrome have other cancer risks, such as increased risk of pancreatic cancer.",
"   </p>",
"   <p>",
"    Effective strategies for breast and ovarian cancer risk-reduction include cancer surveillance, risk-reducing surgery,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemoprevention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women who have not undergone risk-reducing surgery, breast",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ovarian cancer surveillance entails (see",
"      <a class=\"local\" href=\"#H779411428\">",
"       'Cancer surveillance'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Monthly breast self-examination beginning at age 18",
"     </li>",
"     <li>",
"      Clinical breast examination two to four times annually beginning at age 25",
"     </li>",
"     <li>",
"      Annual mammography and breast magnetic resonance imaging (MRI) screening (commonly alternated every six months) beginning at age 25 or individualized based on the earliest age of onset in the family",
"     </li>",
"     <li>",
"      Twice yearly ovarian cancer screening with transvaginal ultrasound and serum CA-125 levels (preferably day 1 to 10 of menstrual cycle for premenopausal women) beginning age 35, or 5 to 10 years earlier than the earliest age of first diagnosis of ovarian cancer in the family",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk-reducing mastectomy is a highly effective strategy for breast cancer risk reduction, decreasing the incidence of breast cancer by as much as 90 percent or more in patients at risk of hereditary breast cancer. It should be considered by women with a BRCA1 or BRCA2 mutation. For women diagnosed with BRCA-ovarian cancer first, we prefer not performing risk-reducing mastectomies until at least five years after the ovarian cancer diagnosis, as survival is dominated by the mortality rate of ovarian cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mastectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk-reducing salpingo-oophorectomy is highly effective in reducing ovarian and fallopian tube cancers in both BRCA1 and BRCA2 mutation carriers (by approximately 80 percent) and breast cancer in premenopausal women. This surgery is recommended to mutation carriers by age 35 to 40 or when childbearing is completed, or individualized based on age of onset of ovarian cancer in the family. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Salpingo-oophorectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who do not opt for risk-reducing surgery may consider surveillance and chemoprevention with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , though this is a less effective alternative to prophylactic mastectomy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Breast cancer chemoprevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral contraceptive use in BRCA1 and BRCA2 mutation carriers appears to decrease the risk of ovarian cancer, but mutation carriers who have used oral contraceptives are still recommended to undergo risk-reducing salpingo-oophorectomy when childbearing is completed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Oral contraceptives for prevention of ovarian cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no single management strategy in reducing the risk of breast and ovarian cancer for all women with HBOC syndrome. The decision is individualized, and is highly dependent upon the patient's own set of values, and these values may change over the course of time (for example, pre- and post-childbearing). The clinician's job is to make the information about each option clear and to support the patient in the decision-making process.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with HBOC syndrome (with BRCA1 and BRCA2 mutations), cancer surveillance includes (see",
"      <a class=\"local\" href=\"#H779411428\">",
"       'Cancer surveillance'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Monthly breast self-examination",
"     </li>",
"     <li>",
"      Clinical breast examination semiannually",
"     </li>",
"     <li>",
"      Baseline mammogram with annual mammography if gynecomastia or",
"      <span class=\"nowrap\">",
"       parenchymal/glandular",
"      </span>",
"      breast density is seen at baseline",
"     </li>",
"     <li>",
"      Appropriate prostate cancer screening",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with BRCA1 or BRCA2 mutations should also have annual full body skin examinations.",
"     </li>",
"     <li>",
"      Patients from high-risk families who are diagnosed with breast cancer may wish to undergo",
"      <span class=\"nowrap\">",
"       BRCA1/2",
"      </span>",
"      testing prior to making treatment decisions, in particular, consideration of an increased risk of ipsilateral and contralateral breast cancer with BRCA-related breast cancer may prompt patients to consider bilateral mastectomy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment and prognosis of women who develop breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/1\">",
"      Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008; 359:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/2\">",
"      Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2010; 8:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/3\">",
"      Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010; 7:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/4\">",
"      Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010; 119:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/5\">",
"      Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20:1260.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/7\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/8\">",
"      Le-Petross HT, Whitman GJ, Atchley DP, et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 2011; 117:3900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/9\">",
"      Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/10\">",
"      Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, et al. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000; 63:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/11\">",
"      Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K. Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 2003; 95:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/12\">",
"      Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003; 21:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/13\">",
"      Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 2003; 97:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/14\">",
"      Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/15\">",
"      Komenaka IK, Ditkoff BA, Joseph KA, et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 2004; 100:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/16\">",
"      Baxter N, Canadian Task Force on Preventive Health Care. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? CMAJ 2001; 164:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/17\">",
"      Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/18\">",
"      Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2010; 28:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/19\">",
"      Rijnsburger AJ, Obdeijn IM, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010; 28:5265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/20\">",
"      Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/21\">",
"      Warner E, Messersmith H, Causer P, et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008; 148:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/22\">",
"      Pijpe A, Andrieu N, Easton DF, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 2012; 345:e5660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/23\">",
"      Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011; 29:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/24\">",
"      Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006; 295:2374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/25\">",
"      Grann VR, Jacobson JS, Thomason D, et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 2002; 20:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/26\">",
"      Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010; 28:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/27\">",
"      Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/28\">",
"      Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/29\">",
"      Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003; 181:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/30\">",
"      Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23:8469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/31\">",
"      Lehman CD, Isaacs C, Schnall MD, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 2007; 244:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/32\">",
"      Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/33\">",
"      Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/34\">",
"      Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/35\">",
"      Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/36\">",
"      Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/37\">",
"      Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 2007; 14:3335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/38\">",
"      Geiger AM, Yu O, Herrinton LJ, et al. A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices. Arch Intern Med 2005; 165:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/39\">",
"      Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/40\">",
"      Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006; 24:4642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/41\">",
"      Sacchini V, Pinotti JA, Barros AC, et al. Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? J Am Coll Surg 2006; 203:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/42\">",
"      Garwood ER, Moore D, Ewing C, et al. Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients. Ann Surg 2009; 249:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/43\">",
"      Domchek SM, Jhaveri K, Patil S, et al. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer 2013; 119:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/44\">",
"      Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/45\">",
"      Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/46\">",
"      NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995; 273:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/47\">",
"      Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 2002; 346:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/48\">",
"      King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/49\">",
"      Eisen A, Weber BL. Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations--facts and controversy. N Engl J Med 2001; 345:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/50\">",
"      Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/51\">",
"      Foulkes WD, Goffin J, Brunet JS, et al. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status. J Natl Cancer Inst 2002; 94:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/52\">",
"      Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006; 118:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/53\">",
"      Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010; 46:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/54\">",
"      Mohamad HB, Apffelstaedt JP. Counseling for male BRCA mutation carriers: a review. Breast 2008; 17:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/55\">",
"      Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/56\">",
"      Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000; 283:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/57\">",
"      van Roosmalen MS, Stalmeier PF, Verhoef LC, et al. Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers. J Clin Oncol 2004; 22:3293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/58\">",
"      Sagi M, Weinberg N, Eilat A, et al. Preimplantation genetic diagnosis for BRCA1/2--a novel clinical experience. Prenat Diagn 2009; 29:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/59\">",
"      Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003; 95:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/60\">",
"      Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004; 22:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/61\">",
"      Trainer AH, Lewis CR, Tucker K, et al. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 2010; 7:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/62\">",
"      Robson M, Svahn T, McCormick B, et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 2005; 103:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/63\">",
"      Chabner E, Nixon A, Gelman R, et al. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1998; 16:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/64\">",
"      Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol 2009; 16:3380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/65\">",
"      Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010; 28:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/66\">",
"      Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27:5887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/67\">",
"      Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 2005; 23:4275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/68\">",
"      Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008; 26:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/69\">",
"      Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 2010; 17:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/70\">",
"      Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010; 102:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/71\">",
"      Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010; :CD002748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/72\">",
"      Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/73\">",
"      Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004; 22:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/74\">",
"      Peshkin BN, Isaacs C, Finch C, et al. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians. J Clin Oncol 2003; 21:4322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/75\">",
"      Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26:4282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/76\">",
"      J&oacute;hannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997; 33:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/77\">",
"      Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25:5846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/78\">",
"      Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/79\">",
"      Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/80\">",
"      Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/81\">",
"      El-Tamer M, Russo D, Troxel A, et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 2004; 11:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/82\">",
"      M&oslash;ller P, Borg A, Evans DG, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002; 101:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/83\">",
"      J&oacute;hannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998; 16:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/84\">",
"      Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006; 17:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/85\">",
"      Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004; 6:R8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/86\">",
"      Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 2010; 119:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/87\">",
"      Lee EH, Park SK, Park B, et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat 2010; 122:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/88\">",
"      de Bree E, Makrigiannakis A, Askoxylakis J, et al. Pregnancy after breast cancer. A comprehensive review. J Surg Oncol 2010; 101:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/0/17418/abstract/89\">",
"      Hemel D, Domchek SM. Breast cancer predisposition syndromes. Hematol Oncol Clin North Am 2010; 24:799.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 758 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17418=[""].join("\n");
var outline_f17_0_17418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H779410859\">",
"      CANCER RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184686209\">",
"      Risks to relatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H166733267\">",
"      CANCER SCREENING AND PREVENTION GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H166733260\">",
"      Recommendations of expert groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H779411428\">",
"      CANCER SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15841789\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15841796\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15841803\">",
"      Breast cancer screening in women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1486483\">",
"      - Mammography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1486490\">",
"      - Breast MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1487041\">",
"      Ovarian cancer screening in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK-REDUCING SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Salpingo-oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHEMOPREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Breast cancer chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Oral contraceptives for prevention of ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H470979705\">",
"      Options for men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL DECISION MAKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H779411749\">",
"      REPRODUCTIVE COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT AND PROGNOSIS OF WOMEN WHO DEVELOP BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/758\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/758|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/27/29104\" title=\"diagnostic image 1\">",
"      Breast MRI screening of BRCA carrier",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5064?source=related_link\">",
"      Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=related_link\">",
"      Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_0_17419="Sun protection measures";
var content_f17_0_17419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sun protection measures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Minimize sun exposure between 10 AM and 4 PM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wear a wide-brimmed hat (4 inches or larger), long-sleeved shirt, and long pants. Choose tightly woven materials or ultraviolet protection factor (UPF) clothing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apply sunscreen when sun exposure is unavoidable. Apply one hour prior to sun exposure to all areas of the skin that are exposed to the sun and reapply frequently (every two hours) and liberally. Use a broad spectrum (UVA and UVB) sunscreen with an SPF of 30 or greater.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be aware of the sun exposure risk with high-altitude activities including mountain climbing, biking, hiking, or skiing, in locations near the equator, and on cloudy or overcast days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Individuals at high risk for skin cancer, such as outdoor workers, fair-skinned individuals, patients with a history of skin cancer, and patients with atypical mole syndrome, should apply sunscreen daily to exposed skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infants less than six months of age should be kept out of the sun; children six months and older should be protected with clothing and sunscreens",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17419=[""].join("\n");
var outline_f17_0_17419=null;
var title_f17_0_17420="B cell subsets";
var content_f17_0_17420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of B cell subsets",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        B-1a",
"       </td>",
"       <td class=\"subtitle1\">",
"        B-1b",
"       </td>",
"       <td class=\"subtitle1\">",
"        B-2, \"Conventional\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD5",
"       </td>",
"       <td>",
"        Constitutive",
"       </td>",
"       <td>",
"        Inducible",
"       </td>",
"       <td>",
"        Inducible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD11b/CD18",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD45RA",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Immunoglobulins",
"       </td>",
"       <td>",
"        Low-affinity",
"       </td>",
"       <td>",
"        High-affinity",
"       </td>",
"       <td>",
"        High-affinity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyreactive",
"       </td>",
"       <td>",
"        Specific",
"       </td>",
"       <td>",
"        Specific",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Germline VH, VL",
"       </td>",
"       <td>",
"        Mutated VH, VL",
"       </td>",
"       <td>",
"        Mutated VH, VL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgM",
"       </td>",
"       <td>",
"        IgG, IgA, IgE",
"       </td>",
"       <td>",
"        IgG, IgA, IgE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Origin",
"       </td>",
"       <td>",
"        Self-replenishing",
"       </td>",
"       <td>",
"        Bone marrow",
"       </td>",
"       <td>",
"        Bone marrow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Location",
"       </td>",
"       <td>",
"        Blood",
"       </td>",
"       <td>",
"        Blood",
"       </td>",
"       <td>",
"        Blood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritoneal cavity",
"       </td>",
"       <td>",
"        Follicular mantle",
"       </td>",
"       <td>",
"        Follicular mantle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD5 ligation",
"       </td>",
"       <td>",
"        Induce TNF and IL-2R",
"       </td>",
"       <td>",
"        Apoptosis",
"       </td>",
"       <td>",
"        Apoptosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     VH: heavy chain variable region genes; VL: light chain variable region genes; TNF: tumor necrosis factor; IL-2R: interleukin-2 receptor. CD45A is the high molecular weight form of CD45 (leukocyte common antigen).",
"    </div>",
"    <div class=\"reference\">",
"     Data from Youinou, P, Jamin, C, Lydyard, PM. Immunol Today 1999; 20:312. (page 314, table2).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17420=[""].join("\n");
var outline_f17_0_17420=null;
var title_f17_0_17421="Neurohumoral activation HF";
var content_f17_0_17421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neurohumoral activation in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depressed ventricular contractility, induced by the underlying cardiac disease, leads to neurohumoral activation (moving clockwise) that is initially adaptive in that it maintains blood pressure and tissue perfusion. Over the long-term, however, the increase in outflow resistance (afterload) hastens the rate of myocardial deterioration and worsens ventricular performance. This leads to a vicious cycle of increasing release of norepinephrine, angiotensin II, and ADH that further increases afterload.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17421=[""].join("\n");
var outline_f17_0_17421=null;
var title_f17_0_17422="Stress MPI after CABG";
var content_f17_0_17422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Stress MPI provides prognostic information after CABG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 351px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In 1544 patients who had previously undergone coronary artery bypass grafting (CABG), stress myocardial perfusion imaging (MPI) was predictive of the subsequent annual cardiac death rate. Cardiac death rates were significantly higher for patients with who had a higher summed stress score (SSS) on MPI; they were also higher in patients evaluated &gt;5 years, as opposed to &le;5 years, after CABG.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zellweger, MJ, Lewin, HC, Lai, S, et al. J Am Coll Cardiol 2001; 37:144.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17422=[""].join("\n");
var outline_f17_0_17422=null;
var title_f17_0_17423="Patient satisfaction post LVRS";
var content_f17_0_17423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51073%7EPULM%2F54029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51073%7EPULM%2F54029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postoperative patient overall satisfaction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 294px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ciccone, AM, Meyers, BF, Guthrie, TJ, et al. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thor Card Surg 2003; 125:513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    SF-36 physical functioning (PF) scale scores from before LVRS (baseline) and after surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 255px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ciccone, AM, Meyers, BF, Guthrie, TJ, et al. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thor Card Surg 2003; 125:513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_0_17423=[""].join("\n");
var outline_f17_0_17423=null;
